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Parkinson’s disease is a progressive neurodegenerative disorder characterized by altered striatal 
dopaminergic signalling that leads to motor and cognitive deficits. Parkinson’s disease is also 
characterized by abnormal presence of soluble toxic forms of alpha-synuclein (α-syn) that, when 
clustered into Lewy bodies, represents one of the pathological hallmark of the disease. However, 
also α-syn oligomers might directly affect synaptic transmission and plasticity in Parkinson’s 
disease models. Accordingly, by combining electrophysiological, optogenetic, 
immunofluorescence, molecular and behavioural analyses, here we report that α-syn reduces N-
methyl-D-aspartate (NMDA) receptor-mediated synaptic currents and impairs corticostriatal long-
term potentiation (LTP) of striatal spiny projection neurons (SPNs), of both direct (D1-positive) and 
indirect (putative D2-positive) pathways. Intrastriatal injections of α-syn produce deficits in visuo-
spatial learning associated with reduced function of GluN2A NMDA receptor subunit indicating 
that this protein selectively targets this subunit both in vitro and ex vivo. Interestingly, this effect is 
observed in SPNs activated by optical stimulation of either cortical or thalamic glutamatergic 
afferents. We also found that treatment of striatal slices with antibodies targeting α-syn prevents the 
α-syn-induced loss of LTP and the reduced synaptic localization of GluN2A NMDA receptor 
subunit suggesting that this strategy might counteract synaptic dysfunction occurring in Parkinson’s 
disease.
KEYWORDS: Dopamine; Glutamate; Long-term potentiation; Monoclonal antibodies; Oligomers; 
Optogenetics; Parkinson’s disease; Synaptic plasticity; Striatum.
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Alpha-synuclein (α-syn) is a 140 amino acids presynaptic protein causally involved in the 
pathogenesis of Parkinson’s Disease (Spillantini and Goedert, 2016). The main mechanisms of α-
syn-mediated cellular damage involve mitochondrial function, endoplasmic reticulum-Golgi 
trafficking, calcium ions influx through formation of pore-like structures, proteins degradation and 
oxidative stress (Gallegos et al., 2015; Wong and Krainc, 2017). 
The protein exists as unstructured monomer widely distributed in the central nervous system and is 
involved in the regulation of presynaptic vesicle pool, neurotransmitter release, synaptic function 
and plasticity (Abeliovich et al., 2000; Cabin et al., 2002). However, α-syn monomers have the 
intrinsic tendency to aggregate in structures of higher molecular weights (Gallegos et al., 2015) and 
in particular conditions, such as pH variations, oxidative stress, mutations and overexpression of α-
syn gene. This process can lead to the formation of α-syn oligomers, protofibrils and eventually 
fibrils, the main components of Lewy Bodies (LBs) (Spillantini et al., 1997; Wong and Krainc, 
2017). While LBs represent a neuropathological hallmark of Parkinson’s disease and the 
histological sign of synucleinopathies, they show no actual direct neurotoxic properties (Tanaka et 
al., 2004). Mechanisms mediating α-syn toxicity in humans have not been determined yet, however, 
several studies point to α-syn oligomers and to protofibrils as major players in synaptic dysfunction 
(Diogenes et al., 2012; Rockenstein et al., 2014). 
The striatum, a subcortical nucleus receiving major excitatory inputs from the cortex and the 
thalamus (Ding et al., 2008), is a brain region particularly involved in Parkinson’s disease and 
oligomeric forms of α-syn may affect synaptic transmission and long-term synaptic plasticity in this 
structure, leading to the motor and behavioural deficits observed in Parkinson’s disease (Tozzi et 
al., 2016). Alpha-synuclein oligomers may produce distinct effects on different striatal neuronal 
subtypes or synaptic sites. In fact, we recently provided evidence that long-term potentiation (LTP) 
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of excitatory synaptic transmission of striatal cholinergic interneurons (ChIs) is impaired by a low 
nanomolar dose of exogenous human α-syn oligomers (Tozzi et al., 2016). In this previous study, 
we found that the loss of LTP in striatal ChIs was induced by a direct effect of α-syn on GluN2D-
expressing N-methyl-D-aspartate receptors (NMDARs), which are selectively expressed in this 
class of interneurons. 
Although in Parkinson’s disease models pathological changes in synaptic plasticity have been 
widely reported in vivo as well as in vitro (Calabresi et al., 2014), at present, no data are available 
on the effects of α-syn on synaptic transmission and synaptic plasticity of striatal spiny projection 
neurons (SPNs) and their possible underlying mechanisms. 
SPNs are GABAergic output neurons, which represent the large majority of neuronal population in 
the striatum (Calabresi et al., 2014). They express a peculiar NMDA subunit receptor composition 
including GluN2A and GluN2B subunits (Dunah et al., 2000; Gardoni et al., 2006), whose distinct 
activation regulates glutamatergic inputs in striatal SPNs. In fact, the selective pharmacological 
modulation of these subunits differentially alters amplitude and kinetics of NMDARs responses 
also affecting responses to dopaminergic modulation (Jocoy et al., 2011; Vastagh et al., 2012). 
Moreover, an unbalanced GluN2A/GluN2B subunit ratio of the striatal synaptic NMDAR is a key 
element in the regulation of motor behaviour and synaptic plasticity in Parkinson’s disease 
(Mellone et al., 2015).
For this reason, it is of great importance to assess whether α-syn could alter synaptic transmission 
and plasticity in striatal SPNs by interfering with different NMDAR subunits. 
In the present study, by utilizing a multidisciplinary approach including electrophysiological, 
optogenetic, immunofluorescence and molecular techniques as well as behavioural testing, we have 
determined the pathological effects of α-syn on the striatal network controlled by NMDAR 
subunits.
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Finally, we have provided the first proof of concept evidence that antibodies against α-syn can 
prevent these pathological synaptic dysfunctions.
MATERIALS AND METHODS
All experimental procedures were conducted in conformity with the European Directive 
2010/63/EU, in accordance with protocols approved by the Animal Care and Use Committee at the 
University of Perugia (Perugia, Italy) and IRCCS Fondazione Santa Lucia (Rome, Italy). 
Animals
For electrophysiological and behavioural experiments we used 2-3 month-old male Wistar rats 
(Charles River, Calco, Italy); 2 month-old transgenic male BAC Drd1a-tdTomato mice containing a 
mouse Drd1a promoter directing the expression of a modified DsRed fluorescent protein (B6.Cg-
Tg(Drd1a-tdTomato)6Calak/J, tdTomato, The Jackson Laboratory, Bar Harbor, Maine, U.S.A.) and 
B6.Cg-Tg(Thy1-COP4/EYFP)18Gfng/J transgenic mice (Thy1-ChR2-YFP) expressing the light-
activated ion channel Channelrhodopsin-2 (ChR2) fused to yellow fluorescent protein under the 
control of the mouse thymus cell antigen 1 (Thy1) promoter. Selective expression of ChR2 has been 
demonstrated both in cortical neurons of layer V and thalamic neurons (Arenkiel et al., 2007; Lim 
et al., 2012).
Animals were housed at 23°C room temperature with food and water ad libitum and a 12-hour 
light-dark cycle. All efforts were made to minimize the number of animals used and their suffering.
Electrophysiology
Coronal brain slices including the cortex and the striatum were cut from Wistar rats and tdTomato 
mice using a vibratome at 220-240 μm thickness. To better preserve the connectivity of thalamic 
fibres to the striatum, para-horizontal slices (250 μm) were cut from Thy1-ChR2-YFP mice for 
optogenetic experiments (Smeal et al., 2007; Ding et al., 2008; Sciamanna et al., 2012). Slices were 
maintained in a Kreb’s solution, bubbled with a 95% O2–5% CO2 gas mixture at room temperature 
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containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 10 glucose, and 25 
NaHCO3 (Calabresi et al., 1992b). Single slices were transferred to a recording chamber and 
submerged in a continuously flowing Krebs’ (34 °C; 2.5–3 ml/minute) bubbled with a 95% O2–5% 
CO2 gas mixture. The internal solution for path-clamp recordings contained (in mM): 145 K+-
gluconate, 0.1 CaCl2, 2 MgCl2, 0.1 EGTA, 10 HEPES, 0.3 Na-GTP and 2 Mg-ATP, adjusted to pH 
7.3 with KOH. For recording NMDAR-mediated currents, neurons were held at +40 mV membrane 
holding potential and the internal solution contained (in mM): 120 CsMeSO3, 10 CsCl, 8 NaCl, 2 
MgCl2, 10 HEPES, 0.2 EGTA, 10 TEA, 5 QX314, 0.3 Na-GTP and 2 Mg-ATP, adjusted to pH 7.3 
with CsOH. Only neurons identified as striatal SPNs were considered for the experiments. 
Normally, for each animal we obtained 2-3 experiments. SPNs were identified by their 
hyperpolarized resting membrane potential (RMP, ~-80 mV), absence of spontaneous action 
potential discharge and presence of tonic firing activity during current-induced membrane 
depolarization. Signals were amplified with a Multiclamp 700B amplifier (Molecular Devices), 
recorded and stored on PC using pClamp10. Whole-cell voltage-clamp recordings (access resistance 
15–30 MΩ; holding potential −80 mV) were performed with borosilicate pipettes (4–7 MΩ) filled 
with the standard internal solution. A bipolar electrode, connected to a stimulation unit (Grass 
Telefactor), was located in the white matter between the cortex and the striatum to stimulate 
glutamatergic fibres (0.1 Hz) and evoke excitatory post-synaptic currents (EPSCs), while the 
recording electrode was placed in the dorsolateral striatum. In all patch-clamp experiments 50 µM 
picrotoxin was added to the external medium to block GABAA receptors. To induce LTP or long-
term depression (LTD), a high-frequency stimulation (HFS) protocol consisting of three trains of 3 
seconds (20 seconds interval) was delivered at 100 Hz. During HFS protocol, the stimulus intensity 
was increased to supra-threshold levels. External Mg2+ ions were omitted to maximize the 
contribution of NMDARs during LTP experiments (Calabresi et al., 1992b). The AMPA receptor 
(AMPAR)- and NMDAR-mediated synaptic currents (AMPA-EPSCs and NMDA-EPSCs) were 
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recorded in pharmacological isolation, with 50 µM picrotoxin plus 50 µM APV and 50 µM 
picrotoxin plus 10 µM CNQX, respectively. AMPAR rectification index (RI) was obtained by 
dividing the AMPA-EPSC amplitude measured at +40 mV by the one measured at -80 mV. 
NMDA/AMPA ratios were calculated by dividing the NMDA-EPSC positive peak amplitude, 
acquired at +40 mM holding potential in the presence of 50 µM picrotoxin plus 10 µM CNQX, by 
the EPSC negative peak amplitude acquired at -80 mV in picrotoxin.
Optogenetic
Optical stimulation of cortex or thalamus was performed using an infinity cube (CAIRN Research, 
UK), consisting of a 470 nm filter system mounted on an Olympus BX-51WI microscope and 
controlled by an Optoflash (CAIRN Research, UK) LED light Switch. The experiments were 
performed on Thy1-ChR2-YFP mice. Light power at microscope objective exit was 2-30 mW/mm2. 
Spotlight was made by utilizing a diaphragm placed along the light path. Slices were illuminated 
from the top and a round spot was created with a radius of approximately 500-600 μm in order to 
avoid light spread to unwanted brain structures and delivered on the cortex or the thalamus. A 3 
mseconds light pulse was delivered every 15 seconds on cortical layer V or in the thalamus in order 
to evoke EPSCs in MSNs.
Preparation of alpha-synuclein in Krebs solution
Different concentrations of α-syn cocktail (3, 10, 30 and 300 nM) (referred in the text as α-syn 
OLIGO) were prepared in Krebs solution bubbled with a 95% O2-5% CO2 gas mixture at room. The 
solutions were incubated up to 1 hour taking aliquots at different time points.
Alpha-synuclein preformed fibrils (PFF) preparation
Lyophilized fresh monomeric α-syn (0.33 mg) (recombinant human α-syn) was dissolved in sterile 
PBS to a final concentration of 1 mg/mL (≈70 µM). 300 µL α-syn-containing buffer has been 
incubated for 7 consecutive days at 37 °C on a shaker (300 rpm) in a sterile 96-well plate. At the 
Page 8 of 101




end of this procedure the α-syn PFF aliquots were stored at -80 °C until the use for intra-brain 
injection. 
Transmission electron microscopy (TEM)
The samples (5 l) were deposited on a glow-discharged Formvar-Carbon 300-mesh coated copper 
grid (Agar Scientific, UK) for 2 minutes, blotted with Whatman filter paper and negatively stained 
with 2% uranyl acetate for few seconds.  Grids were examined with an Energy Filtering 
transmission electron microscope Leo 912 ab (Zeiss, Germany) operating at 100KV and digital 
images were acquired by a CCD camera (Proscan, Germany) 1kx1k with the iTEM software 
(Olympus, Germany).
Detection of alpha-synuclein oligomers in the Krebs solution
A 384-well ELISA microplate (Nunc MaxiSorb, Nunc) was coated by overnight incubation at 4 °C 
with SynO2 (0.2 μg/ml) in 200 mM NaHCO3, pH 9.6 (50 μl/well). The plate was then washed with 
PBST and incubated with 100 μl/well of blocking buffer for 2-hours at 37 °C. After washing, 50 μl 
of the samples (1 nM) was added to each well, and plates were incubated at 37 °C for 2.5-hours. 
FL-140 (rabbit polyclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted in 
blocking buffer at 1:1 K, was added to the appropriate wells, and incubated at 37 °C for 2 h. Next, 
the plate was washed and incubated for 2 h at 37 °C with 50 μl/well of goat anti-rabbit IgG HRP 
(Jackson ImmunoResearch) diluted in blocking buffer (1:15 K). After washing, the plate was 
incubated with 50 μl/well of an enhanced chemiluminescent substrate (SuperSignal ELISA Femto, 
Pierce Biotechnology, Rockford, IL). The chemiluminescence, expressed in relative light units, was 
immediately measured using VICTOR™  X3 multilabel plate reader (PerkinElmer). 
Thioflavin T binding assay
The formation of α-syn oligomers was confirmed by Thioflavin T (ThT) binding assay (Nilsson, 
2004). ThT was incubated at a final concentration of 20 µM in different α-syn solutions (30 nM and 
300 nM, respectively) collected at T0 and after 60 minutes of incubation in Krebs solution bubbled 
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with a 95% O2-5% CO2 gas mixture at room temperature. Emission wavelength scan was performed 
with an excitation wavelength of 450 nm using a plate reader (BMG Labtech Clariostar). The assay 
was performed in triplicate. 
Immunoprecipitation of alpha-synuclein oligomers formed in Krebs solution
500 μl of the samples collected at time points 0 and 30 minutes were incubated with 0.043 and 4.3 
X 10-5 μg/ml of either SynO2 or Syn211 antibodies for 2-hours at room temperature. 100 μl of 
protein G beads was added and incubated for 1-hour at room temperature. The samples were 
centrifuged and the supernatant were collected and checked for the presence of α-syn oligomers by 
ELISA. The bound α-syn oligomers form the beads were eluted by adding 50 μl of 0.2 M glycine 
pH 2.5 and immediately neutralized with 5 μl of 1 M Tris pH 8.0 and taken for western blot 
analysis.
Subcellular fractionation
For the extraction of triton-insoluble postsynaptic fraction (TIF), striatal areas were carefully 
isolated and collected on dry ice from control slices and slices treated with α-syn alone (30 nM) and 
with Abs against α-syn (Syn211 and SynO2). Striatal areas were then homogenized with a Teflon-
glass potter in ice-cold buffer containing (in mM) 320 sucrose, 1 Hepes, 1 MgCl2, 1 NaHCO3, 0.1 
phenylmethylsulfonylfluoride at pH 7.4 in the presence of CompleteTM Protease Inhibitor Cocktail 
Tablets (Roche Diagnostics, Basel, Switzerland) and phosSTOPTM Phosphatase Inhibitor (Roche 
Diagnostics). The sample was spun at 13.000 g x 15 minutes at 4 °C. The resulting pellet was 
resuspended in Triton-KCl buffer (0.5% Triton X-100 and 150 mM KCl) and, after 15 minutes 
incubation on ice, it was spun further at 100.000 g x 1-hour at 4 °C. The pellet (triton-insoluble 
postsynaptic fraction, TIF) was resuspended in 20 mM Hepes buffer supplemented with 
CompleteTM Protease Inhibitor Cocktail Tablets and stored at -80 °C. 
Western blotting (WB)
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The levels of NMDARs and AMPARs in the TIF were analysed by WB. TIF samples were 
separated onto a 7% acrylamide/bis acrylamide gel. Proteins were blotted onto a nitrocellulose 
membrane (Bio-Rad, Hercules, CA, USA) and probed with the appropriate primary antibodies 
followed by the corresponding HRP-conjugated secondary antibodies. Labeling detection was 
performed with ChemiDoc MP Imaging System (Bio-Rad) and images were acquired with 
ImageLab software (Bio-Rad). The primary antibodies used in this study are anti-GluN2A 1:500 
(Sigma-Aldrich, St. Louis, MO, USA), anti-GluN2B 1:500 (Neuromab, Davis, CA, USA), anti-
GluA1 1:1000 (Neuromab), anti-GluA2 1:500 (Neuromab) and anti-tubulin 1:20000 (Sigma-
Aldrich). The latter was always used as loading control for normalization. 
Immunolabeling
Primary antibodies of hu-α-Syn (1:1000, sc-12767, Santa Cruz Biotechnology) in combination with 
hu-α-Syn phosphorylated on Ser129 (hu-α-Syn-phospho S129, ab51253; abcam) or in combination 
with tyrosine hydroxylase (TH 1:500, AB152; Merck Millipore) were used. 30 µm coronal slices, 
obtained with the use of a vibratome (Leica VT1000 S) were incubated overnight at 4 °C with a 
PBS solution containing BSA 0.1% and the combination of two primary antibodies. After rinsing in 
PBS, the sections were incubated for 2-hours with a mixture of secondary antibodies: goat anti-
rabbit Alexa Fluor 647, goat anti-mouse Alexa Fluor 488 (1:300; AP187SA6 and AP124JA, Merck 
Millipore). After subsequent washes in PBS, brain slices were incubated with DAPI (S7113; Merck 
Millipore) for 10 minutes and finally mounted on gelatin-coated slides and coverslipped. The 
specificity of immunoreaction was controlled by omitting primary antibodies. Images of the medial 
and lateral striatum (60x magnification) were taken using a fully motorized confocal microscope 
Nikon A1 and Nikon NIS Elements Advanced Research software. 
Surgery 
A total of 30 male Wistar rats (Charles River, Italy) were housed three x cage with free access to 
chow and water under a 12:12 h light–dark cycle. All surgical operations were performed under 
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ketamine/xylazine anaesthesia. Animals received two bilateral intrastriatal injections of either α-syn 
PFF (n=9), OLIGO (n=6) or PBS (control, n=15). The volume injected using a 10 μl Hamilton 
microsyringe was 1 μl for each site. The injection rate was 0.38 μl/minute and for each site the 
cannula was left in place for additional 2 min before retracting it. The coordinates, based on a 
previous study using these parameters to perform striatal lesions (Kirik et al., 1998), were the 
following: 1) anteroposterior (AP) +1.0; mediolateral (ML) +3.0; dorsoventral (DV) -5.0; 2) AP 
+1.0; ML -3.0; DV -5.0. ML coordinates were taken from lambda, AP coordinates were from 
bregma, according to Paxinos and Watson (Paxinos, 2005). Tooth bar was set at 0.00. After the 
surgery the animals were monitored until awake and then brought back to animal facility. Six weeks 
after the surgery the animals were tested for motor behaviour and cognition deficit.
Visuo-Spatial Memory Task
Visuo-Spatial Memory Task was a rat adapted version of the visuo-spatial memory task previously 
described in mouse (De Leonibus et al., 2007; De Leonibus et al., 2009; Rodo et al., 2017). The test 
was divided in 10 sessions of 5 minute each. The interval between the sessions was 3 minutes. 
Briefly, during session 1 (S1), rats were placed in an empty a square open field to habituate to the 
context (60x60 cm).  After this, from session 2 to session 7 (S2-S7), rats were free to explore three 
objects positioned in the arena to allow them to learn information about the objects and their spatial 
location in the arena (habituation phase). To test whether the animals learned spatial information 
related to the position of the objects, during the spatial test session 8 (S8), the objects configuration 
was changed by moving one object (the displaced object, DO) and leaving the other two objects in 
the same position (non-displaced objects, NDO1 and NDO2). In session 9 (S9), the configuration of 
the objects was kept unchanged to let the animal to habituate to the spatial change. In the last 
session (S10), to test whether animals learned information about the shape of the object, one of the 
familiar objects was replaced by a new one (substituted object, SO); the other two objects were left 
unchanged (non-substituted objects, NSO1 and NSO2). Object exploration was defined as the time 
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in which the nose of the animal was in directed toward the object (<2 cm distance). The animals’ 
ability to selectively react to the spatial change was analysed by calculating the spatial exploration 
index (DO=DO [S8]−DO [S7]; NDO=NDO [S8]−NDO [S7]), while the animals’ ability to 
selectively react to the non-spatial change (novel object) was analysed by calculating non-spatial 
exploration index (SO=SO [S10]−SO [S9]; NSO=NSO [S10]−NSO [S9]). Basal motor activity was 
evaluated during S1, by measuring time interval changes in distance travelled (cm), immobility time 
(seconds) and maximal speed (cm/second). 
Statistical Analysis
Data analysis of electrophysiological experiments was performed off-line using Clampfit10 
(Molecular Devices) and GraphPad Prism 5.0 (GraphPad Software). Values in the text and figures 
are mean ± standard error of the mean (SEM), n representing the number of recorded neurons. 
Changes of EPSC amplitude induced by drugs or by stimulation protocols were expressed as a 
percentage of the baseline, the latter representing the normalized EPSC mean amplitude acquired 
during a stable period (10–15 minutes) before delivering drugs or stimulation and statistically 
evaluated by the Student’s t-test for unpaired samples. LTP and LTD presence were statistically 
verified with the Student’s t-test for paired samples by comparing in each experiment values of the 
EPSC amplitudes at 25–30 minutes after the application of the HFS protocol relatively to the 
baseline. Current-voltage (I-V) curves were compared using the two-way ANOVA. The 
significance level was established at P<0.05. For WB experiments, significance of the differences 
was determined by one-way ANOVA followed by Tukey’s post-hoc test or by unpaired Student’s t-
test as appropriate. For ThT binding assay significance of the differences was determined by 
Student’s t-test. For behavioural analysis, data were analysed by using two-way Analysis of 
Variance (ANOVA) for repeated measure, with treatment (two levels: control and α-syn) as 
between factor. Duncan post hoc analysis was used when appropriate. 
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When parametric tests were used, normality was checked with Shapiro-Wilk test and visual 
inspection of data distribution. The criterion for significance was set at P<0.05. We used Shapiro-
Wilk test for its level of power compared to other procedures in small sample size scenarios 
(Royston, 1993).
Drugs
Picrotoxin, D-(-)2-amino-5-phosphonopentanoic acid (APV), 6-cyano-7- nitroquinoxaline-2,3-
dione disodium (CNQX), threo ifenprodil hemitartrate, 3-chloro-4-fluoro-N-[4-[[2-
(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulfonamide (TCN-201), NVP-AAM077 were 
from Tocris; dopamine hydrochloride (DA) was from Sigma.
Drugs were bath-applied by switching the Kreb’s solution to one containing known concentrations 
of drugs. Drugs applied in the recording chamber were delivered for at least 10 minutes before 
recording AMPA-EPSC and NMDA-EPSC and maintained throughout the experiment. We used 
two different mouse antibodies against α-syn: a monoclonal IgG1 Ab, raised against the amino acid 
121-125 of human α-syn, which recognizes all forms of the protein (Syn211, Santa Cruz 
Biotechnology, Inc.,) (El-Agnaf et al., 2003) and a monoclonal IgG1 Ab which has a higher affinity 
to oligomers more than α-syn fibrils (SynO2) (Vaikath et al., 2015). Abs and α-syn were provided 
by Prof. O. El-Agnaf (U.A.E. University, United Arab Emirates). Corticostriatal slices were 
incubated in a solution containing 8.6 µg α-syn, corresponding to a dose of 30 nM, plus the Ab for 1 
hour (1:1, µg/µg). The Syn211 Ab was further diluted 1:10 (0.043 µg/ml) and 1:100 (0.0043 
µg/ml), while SynO2 Ab was used at dilution 1:10.000 (4.3 x10-5 µg/ml).
RESULTS
Alpha-synuclein does not affect basal membrane properties and LTD but impairs LTP in 
striatal SPNs
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In order to characterize the α-syn effect on striatal SPNs we first explored the effect of this protein 
on the basal membrane properties performing patch-clamp recordings of SPNs in striatal slices 
obtained from 2-3 months-old rats. The current-voltage relationship was evaluated applying 
hyperpolarizing and depolarizing steps of currents to SPNs of control slices and of slices incubated 
for 1-hour with 30 nM monomeric/oligomeric α-syn freshly diluted in the Kreb’s solution (see 
Materials and Methods). We found that the measured electrical properties were unaffected by α-syn 
since statistical analysis showed no significant differences in the I-V curves between SPNs recorded 
in control slices (n=5) and in slices treated with α-syn (n=4) (control vs α-syn, P>0.05) (Fig. 1A). 
Striatal slices were subsequently tested to assess the effect of 30 nM α-syn on long-term changes of 
synaptic transmission (LTD and LTP) of SPNs. EPSCs were recorded for 10 minutes to obtain a 
stable baseline and then for 30 minutes after the application of the HFS protocol. We found that 
SPNs recorded in control and in α-syn-incubated slices showed LTD of similar amplitudes 
(Calabresi et al., 1992a). In fact, the EPSCs amplitude was reduced by 46.0 ± 2.8% (n=6) and by 
49.8 ± 2.1% (n=6) in SPNs from control slices and α-syn-incubated slices, respectively (t(10)=1.094, 
P<0.05, pre vs 30min after HFS, Fig. 1B). To explore the effect of α-syn on SPNs LTP, EPSCs 
were recorded before and for 30 minutes after the application of magnesium free HFS protocol. 
While SPNs from control slices showed a robust LTP of 148.7 ± 3.2% (n=7, t(6)=15.37, P<0.001), 
neurons from α-syn-treated slices showed no LTP (n=7, P>0.05, pre vs 30min after HFS, Fig. 1C).
We also analysed the EPSC amplitude, measured 30 min after the induction of the LTP, in the 
presence of different concentrations of α-syn. We found that while 3 nM α-syn (n=6) did not affect 
this parameter, both 10 nM (n=7) and 30 nM (n=7) produced a significant reduction. Higher 
concentrations of α-syn (300 nM, n=6) did not further decrease the EPSC amplitude (Fig. 1D). 
It has been postulated a major detrimental effect of α-syn is the reduction of striatal dopamine (DA) 
levels (Ghiglieri et al., 2018), thus the α-syn-induced LTP impairment could be induced by lower 
DA levels in the synaptic cleft. To test this hypothesis, 30 µM exogenous DA were bath applied 
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before the HFS in order to obtain a recovery of the LTP in the presence of α-syn (n=6). 
Surprisingly, DA failed to restore this form of synaptic plasticity suggesting that other non-
dopaminergic mechanisms might be involved in the loss of LTP in the presence of α-syn (Fig. 1E).  
In order to investigate the time- and dose-dependent formation of α-syn oligomers in the Krebs 
solution used for the electrophysiological experiments, α-syn samples at time 0 and 30 min were 
taken and measured by specific oligomeric ELISA. As expected, the formation of α-syn oligomers 
was time- and dose-dependent (Fig. 1F, *P<0.05, **P<0.01), as higher level of α-syn oligomers 
were detected in the 300 nM α-syn samples collected at 30 min. To evaluate the presence of fibrils 
we used the Thioflavin T (ThT) fluorescence assay; the results clearly show that little fluorescence 
was detected with the 30 nM concentration, independently on the timing of sampling (Fig. 1G, 
***P<0.001). 
Alpha-synuclein affects SPNs glutamatergic transmission by selectively targeting the GluN2A-
NMDAR current, but not the GluN2B-NMDAR and AMPAR currents
We then evaluated the effect of α-syn on the AMPA- and NMDA-EPSCs since both these glutamate 
receptors exert a pivotal role in the long-term changes of synaptic plasticity of SPNs. To isolate 
AMPA-EPSCs, SPNs were recorded in the presence of 50 µM of the NMDAR antagonist APV and 
50 µM of the GABAAR antagonist picrotoxin. After obtaining stable EPSCs for 10 minutes, 
synaptic currents were measured in the presence of 30 nM α-syn for additional 10 minutes. We 
found no significant difference between AMPA-EPSCs recorded before and following α-syn 
application (n=6, P>0.05, Fig. 2A). We also evaluated the AMPAR rectification index (RI) 
calculated in control conditions and in the presence of 30 nM α-syn (Fig. 2B). Statistical analysis 
shows that in these conditions the AMPA RI was not significantly different from that measured 
before α-syn application (n=6, P>0.05, Fig. 2B), further suggesting that in SPNs α-syn does not 
alter the function of AMPAR.
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We also explored whether α-syn affected the NMDAR by targeting the GluN2A- or the GluN2B-
mediated NMDA-EPSC (GluN2A-EPSC and GluN2B-EPSC). To isolate the GluN2A-EPSC, 
synaptic responses were recorded in the presence of 10 µM of the AMPAR antagonist CNQX, 50 
µM picrotoxin and 3 μM of the GluN2B antagonist ifenprodil. We found that after recording a 
stable baseline for 10 minutes, the subsequent application of 30 nM α-syn significantly reduced the 
GluN2A-EPSC by 40.8 ± 6.1% (n=6, t(5)=6.684, P<0.05, Fig. 2C). We subsequently isolated the 
GluN2B-EPSC by recording synaptic responses in the presence of CNQX, 50 nM of the GluN2A 
antagonist NVP-AAM077 and picrotoxin. The application of 30 nM α-syn did not affect the 
GluN2B-EPSC (n=6, P>0.05, Fig. 2D). Similarly, we found that the GluN2B-EPSC, isolated using 
the more specific GluN2A antagonist TCN-201 (10 µM), was not significantly affected by α-syn 
application (n=6, P>0.05, Fig. 2E). Taken together these findings show that α-syn affects the SPNs 
NMDA-EPSC selectively targeting the GluN2A-containing NMDA receptors. Moreover, we also 
evaluated, by WB analysis in a triton-insoluble post-synaptic fraction (TIF), the possibility that 
alterations in the molecular composition of ionotropic glutamate receptors may lead to the observed 
synaptic alterations in SPNs induced by α-syn. In line with the electrophysiological experiments, we 
found that incubation (1-hour) of the slices in 30 nM α-syn did not alter GluA1 and GluA2 AMPAR 
subunit synaptic levels (n=8, P>0.05, α-syn vs control, Fig. 2F) while it significantly reduced the 
GluN2A but not GluN2B NMDAR subunit synaptic levels (n=6, GluN2A, P=0.014, α-syn vs 
control, Fig. 2G).
GluN2A but not GluN2B NMDAR subunit plays a critical role in the induction of LTP in 
SPNs 
To ascertain the involvement of GluN2A and GluN2B NMDAR subunits in LTP, we first induced 
this form of synaptic plasticity in the presence of 3 µM of the GluN2B antagonist ifenprodil, to 
isolate the GluN2A-EPSC. In these conditions we found a normal LTP since the increase of EPSCs 
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amplitude obtained after the delivery of HFS protocol was not different from that one of control 
slices (control, 147.2 ± 3.0%, n=6; ifenprodil, 143.3 ± 2.8%, n=5, P>0.05, Supplementary Fig. 1). 
Conversely, the application of the GluN2A antagonists NVP-AAM077 (50 nM, n=5) or TCN-201 
(10 µM, n=5) completely prevented the LTP induction (P>0.05, Supplementary Fig. 1), further 
confirming that the NMDAR expressing the GluN2A subunit mediates the LTP induction of striatal 
SPNs.
Alpha-synuclein affects LTP and NMDAR-mediated synaptic currents in SPNs of both direct 
and indirect pathways
To investigate whether SPNs expressing either the D1-like or D2-like DA receptors (Calabresi et 
al., 2014) were differentially affected by α-syn, we recorded SPNs from striatal slices of dtTomato 
mice. In these animals, we firstly optically identified fluorescent (D1-like expressing: D1R-
positive) and non-fluorescent (putative D2-like expressing: putative D2R-positive) SPNs (Fig. 3A). 
Subsequently, we patch-clamped SPNs for an electrophysiological characterization and for LTP 
analysis in both these neuronal sub-populations. We found that both fluorescent (D1R-positive) and 
non-fluorescent (putative D2R-positive) SPNs showed LTP of similar amplitude. In fact, 30 
minutes after the induction of the HFS protocol, the EPSC amplitude was increased respect to the 
baseline by 134.6 ± 4.0% (n=6, t(5)=11.33, P<0.001) and 137.1 ± 5.9% (n=6, t(5)=5.452, P<0.001), 
respectively in fluorescent and non-fluorescent SPNs (Fig. 3B). 
Moreover, we aimed at verifying whether α-syn equally affected LTP of SPNs of both neuronal 
sub-populations. Striatal slices from dtTomato mice were incubated for 1-hour with 30 nM α-syn. 
In these conditions we found that the induction of LTP was completely prevented in both 
fluorescent (n=5, P>0.05) and non-fluorescent SPNs (n=5, P>0.05) (Fig. 3C-D). 
Since α-syn affected NMDA-EPSCs (Fig. 2C-E), we tested whether this glutamatergic current was 
differentially altered by α-syn in SPNs expressing and not expressing (putative D2R-positive) the 
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D1 DA receptor. The NMDA-EPSC amplitudes were recorded in pharmacological isolation in the 
presence of 50 µM picrotoxin plus 10 µM CNQX in both fluorescent and non-fluorescent SPNs of 
dtTomato mice. After acquiring a stable baseline for 10 minutes, 30 nM α-syn was bath applied for 
subsequent 10 minutes. We found that α-syn significantly reduced the NMDA-EPSC in both SPN 
populations. The EPSCs were reduced by 27.2 ± 4.2% in D1R-positive SPNs (n=6, t(5)=6.510, 
P<0.05, Fig. 3E) and by 30.1 ± 6.3% in putative D2R-positive SPNs (n=4, t(3)=4.764, P<0.05, Fig. 
3F) and the amplitude of these reductions was similar in these two groups of SPNs (P>0.05). These 
findings suggest that α-syn exerts similar effects in SPNs of the direct and indirect basal ganglia 
pathways equally affecting the NMDAR-mediated synaptic current.
Alpha-synuclein affects the NMDAR-current evoked in SPNs by cortico-striatal and thalamo-
striatal optical stimulation
Our data suggest that α-syn reduced the GluN2A-EPSC amplitude following the stimulation of 
glutamatergic afferents to the striatum. However, striatal SPNs receive glutamatergic inputs by both 
the cortex and the thalamus and these pathways might be differentially regulated by 
pharmacological agents (Wu et al., 2015). Thus, we investigated whether α-syn affected the 
NMDAR-mediated transmission in cortico-striatal synapses as well as in the thalamo-striatal 
pathway by using an optogenetic approach to better dissect inputs from these two brain structures. 
We firstly recorded NMDA-EPSCs in pharmacological isolation to evaluate the contribution of the 
GluN2A and GluN2B NMDAR subunits in cortico-striatal and thalamo-striatal synapses and then 
analysed the effect of α-syn on these currents (Fig. 4A-H). SPNs EPSCs, evoked by optical 
stimulation of cortico-striatal projections, were recorded from Thy1-ChR2-YFP mice. GluN2A- or 
GluN2B-EPSCs were isolated in the presence of 50 µM picrotoxin, 10 µM CNQX and 3 µM 
ifenprodil (GluN2B antagonist) or 10 µM TCN-201 (GluN2A antagonist), respectively. 
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We found that the NMDA-EPSC was significantly reduced by 45.46 ± 3.29% in the presence of the 
solution containing ifenprodil and by 35.04 ± 5.47% in that with TCN-201 (ifenprodil, n=6, 
t(5)=13.86, P<0.0001; TCN-201, n=6, t(5)=6.405, P<0.05, Fig. 4C). We subsequently tested the 
effect of α-syn on the isolated GluN2A- and GluN2B-EPSC. 30 nM α-syn significantly reduced the 
GluN2A-EPSC by 40.82 ± 4.46% (n=6, t(5)=9.148, P<0.05, Fig. 4D). This effect was observed at 5, 
but not at 2 minutes, after the α-syn application (at least n=4 for all the time points, P<0.001, Fig. 
4D). Notably, longer α-syn applications (10 minutes) did not further decrease the NMDA current. 
Interestingly, we found no effect of α-syn on the GluN2B-EPSC at all time-points tested (at least 
n=4 for all time points, P>0.05, Fig. 4D).
Striatal SPNs EPSCs were also evoked by optical stimulation of the thalamus of Thy1-ChR2-YFP 
mice to evaluate the contribution of the GluN2A and GluN2B currents in the NMDAR response 
activated by thalamic glutamatergic fibres. NMDA-EPSCs, recorded in the presence of picrotoxin 
plus CNQX, were significantly reduced by 34.08 ± 2.87% in the presence of ifenprodil (n=5, 
t(4)=11.87, P<0.05, Fig. 4F) and by 32.98 ± 3.12% in TCN-201 (n=6, t(5)=10.57, P<0.05, Fig. 4F).
Isolated GluN2A and GluN2B currents were subsequently measured in the presence of α-syn. We 
found that in these conditions the GluN2A-EPSCs were reduced by 42.35 ± 4.0% (n=7, t(6)=10.58, 
P<0.0001, Fig. 4G) while, similarly to what observed for GluN2B-EPSCs evoked by optical 
cortico-striatal stimulation, α-syn had no effect on the GluN2B currents (n=7, P>0.05, Fig. 4G). 
This effect was observed at 5 after the α-syn application. Notably, also in this case longer α-syn 
applications did not further decrease the NMDA current and we found no effect of α-syn on the 
GluN2B-EPSC at all time-points tested (at least n=3 for all time points, P>0.05, Fig. 4G).
Monoclonal antibodies targeting α-synuclein rescue the impairment of LTP 
Alpha-synuclein is a small protein with intrinsic tendency to aggregate. Oligomeric forms of the 
protein can impair neuronal function (Diogenes et al., 2012; Rockenstein et al., 2014). Accordingly, 
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we found that 30 nM α-syn cause LTP loss in SPNs by affecting the GluN2A NMDAR-mediated 
current. To counteract the effect of α-syn on SPN LTP we used the monoclonal Ab Syn211, that 
recognizes all forms of human α-syn (Giasson et al., 2000) and the Ab SynO2, which mainly 
recognizes early soluble oligomers and late aggregates amyloid fibrils of α-syn (Majbour et al., 
2016).
Incubation of the slices for 1 hour with the Syn211 Ab 1:10 alone did not affect LTP (158.3 ± 7.4%, 
n=7, t(6)=6.863, P<0.001, Fig. 5A). However, incubation of the slices for 1 hour with the Syn211 Ab 
1:10 in combination with 30 nM α-syn was able to prevent the loss of LTP induced by α-syn (153.0 
± 54.9%, n=7, t(6)=10.52, P<0.0001, Fig. 5A). Conversely, a lower Ab concentration (1:100) was 
not sufficient to counteract the α-syn effect on LTP amplitude; in fact, SPNs recorded in the 
presence of Syn211 Ab 1:100 plus 30 nM α-syn showed no LTP (n=7, P>0.05, Supplementary Fig. 
2).
We subsequently tested the effect of SynO2 Ab, which recognizes oligomeric forms of α-syn more 
specifically than fibrillar forms. We found that while a very low concentration (1:10.000) of this Ab 
did not affect LTP per se (143.2 ± 3.8%, n=7, t(6)=13.33, P<0.0001, Fig. 5B), it rescued this form of 
synaptic plasticity when incubated in the presence of 30 nM α-syn (140.9 ± 3.8%, n=7, t(6)=12.01, 
P<0.0001, Fig. 5B). Taken together these data suggest that Abs against α-syn represent a valid tool 
for preventing the detrimental effect of α-syn on striatal synaptic plasticity.
Next, we tested the ability of SynO2 and Syn211 antibodies to capture α-syn oligomers formed 
during incubation in Krebs solution. We conducted immunoprecipitation experiment with the 
samples collected at time 0 and 30 minutes with antibodies (SynO2 or Syn211) and estimated the α-
syn oligomers left in the sample using our oligomeric ELISA. Interestingly, when the samples were 
immunoprecipitated using SynO2, the supernatant contained very low levels of α-syn oligomers 
with both high and low concentrations (Fig. 5C, left and right panel respectively), suggesting 
sequestration of α-syn oligomers species with high efficacy (Fig. 5C, **P<0.01). Whereas, 
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incubation with Syn211 antibody exerted a milder effect, and higher levels of α-syn oligomers were 
detected in the supernatant (Fig. 5C, **P<0.01). This dose-response nicely parallels that observed in 
their relative efficacy in rescuing the LTP impairment induced by α-syn oligomers (Fig. 5A-B).
Incubation with alpha-synuclein specifically affects GluN2A localization at the post-synaptic 
membrane
Notably, incubation of the slices with Syn211 Ab 1:10 or with SynO2 Ab 1:10.000 in combination 
with 30 nM α-syn was sufficient to prevent the reduction of GluN2A levels in the postsynaptic 
compartment (n=6-11, P<0.01, control vs α-syn; P<0.05, Syn211 plus α-syn vs α-syn; P<0.05, 
SynO2 plus α-syn vs α-syn, Fig. 5D-E). In agreement with LTP results (see Supplementary Fig. 2), 
incubation of the slices with Syn211 Ab 1:100 did not revert the effect of 30 nM α-syn on GluN2A 
synaptic levels (n=7-11, P<0.01, control vs α-syn, Supplementary Fig. 3). No effect of 30 nM α-syn 
on synaptic localization of GluN2B subunit of NMDAR or GluA1 and GluA2 subunits of AMPAR 
was observed either in absence or presence of co-incubation with Syn211 Ab 1:10 or with SynO2 
Ab 1:10.000 (Supplementary Fig. 4A-D). Overall these results indicate that the observed decrease 
in GluN2A-NMDARs current induced by α-syn is directly correlated to a reduction of the synaptic 
availability of this receptor subunit.
Intrastriatal injections of alpha-synuclein protofibrils impairs visuo-spatial learning
To test in vivo the effects of human α-syn aggregates, we injected directly into the dorsal striatum 
preformed α-syn fibrils (PFF), which is an already characterized progressive model of 
synucleinopathy. In fact, using a similar approach, a time-dependent spreading of α-syn and 
neuronal degeneration has been reported about 9 months after the injection (Luk et al., 2012), while 
spreading all over the brain. Figure 6A shows the Transmission Electron Microscopy (TEM) 
analysis of protofibrils and shorter aggregates (putative oligomers) injected into the rat striatum. We 
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decided to test the effects at 6 weeks post-injection (Fig. 7A-B); at this time point aggregates, and 
other α-syn forms, are evidenced through their reaction with the phospho-Ser129hu-α-Syn antibody 
(in red) and remained localized into the dorsal striatum (Fig. 6B-C).
To test whether behavioural performance was affected, PBS- and α-syn-injected rats were subjected 
to a visuo-spatial learning task. The task is based on a habituation/dishabituation paradigm in which 
animals during the habituation phase (from session 2 to session 7), through direct exploration, 
acquire information about 3 different objects and their spatial location in the arena (Fig. 7A-B). 
After this acquisition phase, one of the objects is displaced (session 8); the spatial preference for the 
displaced object (DO) over the non-displaced objects (NDO) is an index of spatial novelty 
detection. As reported in figure 7B, α-syn-injected rats, as well as PBS-injected animals, explore the 
objects during the habituation phase, reducing the exploration time across sessions [Treatment 
(F1,15=0.026; P=0.874); Exploration (F5,75=7.673; P<0.0001); Exploration x Treatment (F5,75=0.75; 
P=0.589)] (Fig. 7B). After the spatial displacement the PBS group showed a preference for DO as 
compared to NDO1 and NDO2, as expected; in contrast, the α-syn-injected group did not show any 
preference for the DO [Treatment (F1,15=0.152; P=0.702); DO (F2,30=3.387; P=0.047); DO x 
Treatment (F2,30=3.347; P=0.049)]. This effect was not due to a general effect on object exploration, 
attention or motivation to explore novelty, as both groups sho ed a clear preference when the same 
object was substituted with a new one (SO) during the last testing session [Treatment (F1,15=0.348; 
P=0.564); SO (F2,30=15.153; P<0.0001); SO x Treatment (F2,30=0.87; P=0.429)].
Intrastriatal injections of alpha-synuclein aggregates impair the SPNs GluN2A-bearing 
NMDAR-current
We subsequently attempted to test the possible causal link among the presence of striatal α-syn 
aggregates, the synaptic transmission deficits, as observed in the in vitro electrophysiological 
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experiments using α-syn oligomers, and the behavioural deficits of α-syn-injected rats in 
performing the visuo-spatial learning task. 
A group of human α-syn- and sham-injected rats were sacrificed one week after the behavioural 
task. SPNs of the two groups were patch-clamped and EPSCs were evoked at -80 mV holding 
potential, in the presence of 50 µM picrotoxin, and at +40 mV, in picrotoxin plus 10 µM CNQX, to 
calculate the NMDA/AMPA ratio of the synaptic current. Statistical analysis revealed that SPNs of 
α-syn-injected rats presented reduced NMDA/AMPA ratio in respect to sham-injected animals (α-
syn vs sham, n=5 for each group, t-test, t(8)=6.6, P<0.001; Fig. 7C). In addition, since α-syn 
oligomers specifically reduced the GluN2A-bearing NMDAR-currents (Fig. 2C), EPSCs of SPNs 
from α-syn- and sham-injected rats were also recorded at +40 mV holding current in the presence of 
CNQX plus 3 µM ifenprodil to measure the GluN2A-EPSC amplitude. We found that in SPNs of α-
syn-injected rats the GluN2A-current was significantly smaller than that of sham rats (α-syn vs 
sham in ifenprodil, t-test, t(11)=2.2, P<0.05; Fig. 7D) confirming that the spreading of α-syn 
aggregates into the striatum affects the striatal synaptic transmission by reducing the SPN GluN2A-
NMDA current with significant implications on behavioural learning. 
       
Behavioural effects produced by intrastriatal injection of oligomeric alpha-synuclein
Intrastriatal injections of human α-syn aggregates, containing protofibrils but also shorter forms (see 
Fig. 6A), clearly produced behavioural and synaptic alterations (See Fig. 7). These alterations could 
be due either to the action of oligomeric and monomeric α-syn forms, similar to those applied in our 
in vitro experiments, or to the critical presence of fibrillary PFF forms of this protein. Thus, to 
better dissect the pathogenetic role of different species of α-syn (protofibrils versus oligomers and 
monomers), we performed a similar in vivo intrastriatal injection with α-syn cocktail mainly 
containing oligomers (OLIGO).  
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We injected the α-syn cocktail (α-syn OLIGO) directly into the dorsal striatum (Fig. 8A-B), using 
the same protocol used for PFF. As previously indicated for PFF (see Fig. 6A), also the presence of 
α-syn OLIGO has been detected by TEM (Fig. 8A). Electron Microscopy was always used to 
analyse the quality of α-syn preparations before injection into the rat striatum confirming the 
presence of oligomers with very few protofibrils (Fig. 8A). In addition, α-syn OLIGO has been 
confirmed by immunofluorescence with antibodies against α-syn and phospho-α-syn (Fig. 8B-C). 
 As reported in Fig. 8D-F, α-syn OLIGO-injected rats, as well as PBS-injected animals, explore the 
objects during the habituation phase, reducing the exploration time across sessions [Treatment 
(F1,10=0.86; P=0.375); Exploration (F5,50=9.65; P<0.0001); Exploration x Treatment (F5,50=0.45; 
P=0.80)] (Fig. 8D). The α-syn OLIGO-injected group did not show any preference for the DO 
[Treatment (F1,10=0.138; P=0.702); DO (F2,20=8.039; P=0.0027); DO x Treatment (F2,20=4.7; 
P=0.02)] and SO [Treatment (F1,10=0.713; P=0.41); SO (F2,20=8.70; P=0.0019); SO x Treatment 
(F2,20=3.99; P=0.03)] (Fig. 8E-F), thus suggesting that it impaired both spatial and object novelty 
recognition, in the absence of major degeneration of TH positive terminals in the striatum 
(Supplementary Fig. 5). 
Analysis of basal motor activity in the open field reveals that at this early stage neither animals 
injected with protofibrils nor animals injected with α-syn OLIGO show significant changes of 
motor behaviour (Supplementary Fig. 6).
DISCUSSION
In this study we have investigated the effects of exogenous human α-syn on synaptic transmission 
and plasticity of SPNs, the main neuronal subtype of the striatum. We obtained four novel findings: 
1) α-syn impairs LTP by altering the activity of the GluN2A-containing NMDARs in SPNs 
belonging to the direct and indirect basal ganglia pathways; 2) α-syn produces a reduction of 
NMDAR-mediated currents in SPNs optically activated by stimulation of either cortical or thalamic 
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afferents; 3) the application of α-syn-neutralizing antibodies prevents the widespread impairment of 
striatal LTP; 4) intrastriatal injection of α-syn PFF produces deficits in visuo-spatial learning and 
GluN2A NMDA receptor function; 5) the intrastriatal injection of oligomers (α-syn OLIGO) 
mimics the behavioural effects produced by PFF, causing an even more severe visuo-spatial 
alteration. These data suggest that oligomeric/monomeric forms play a more relevant role than 
fibrillary forms on striatal-dependent behaviour.
Striatal dysfunction as an early effect of alpha-synuclein toxicity 
The complex alterations of the basal ganglia pathways in Parkinson’s disease involve degeneration 
of nigral DA neurons that leads to reduced striatal DA content and impaired synaptic plasticity of 
SPNs (Calabresi et al., 2007; Gerfen and Surmeier, 2011). These changes are accompanied by 
accumulation of α-syn (Spillantini and Goedert, 2016), exerting a toxic role in Parkinson’s disease 
in its oligomeric forms (Conway et al., 1998; Winner et al., 2011; Rockenstein et al., 2014) rather 
than in the fibrillar state or when clustered into LBs (Ghosh et al., 2015). 
Although it has been previously reported that in the hippocampus micromolar concentrations of 
extracellular α-syn oligomers are able to impair LTP and to increase basal synaptic transmission 
through a NMDAR-mediated action (Diogenes et al., 2012), little is known on the direct effects of 
α-syn oligomers on striatal neurotransmission, a fundamental player in the regulation of voluntary 
motor function in physiological conditions and in Parkinson’s disease. Our findings, demonstrating 
widespread involvement of much lower (nanomolar) concentrations of α-syn oligomers in the 
alteration of synaptic transmission in striatal SPNs, are particularly relevant given the role exerted 
by altered forms of this protein in Parkinson’s disease (Polymeropoulos et al., 1997; Spillantini et 
al., 1997; Vekrellis et al., 2011). These results extend our previous findings demonstrating that α-
syn oligomers is able to block LTP of striatal ChIs at lower concentrations (3 nM) respect to that 
effective on SPNs in the present study (30 nM), by selectively modulating the GluN2D-expressing 
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NMDA receptors (Tozzi et al., 2016). Taken together these findings suggest that increasing 
concentrations of α-syn oligomers progressively affect NMDAR-mediated synaptic plasticity on 
distinct neuronal populations indicating that the vulnerability to this protein is cell- and region-
specific.
Distinct vulnerability of different NMDA receptor subunits to alpha-synuclein 
We found that α-syn impairs NMDAR-dependent LTP in striatal SPNs with no detrimental effect 
on LTD, according to the observation that this latter form of synaptic plasticity in the striatum does 
not require NMDAR activation (Calabresi et al., 2007).
We observed that α-syn affected SPNs glutamatergic transmission by selectively affecting GluN2A-
expressing NMDAR currents. This is a remarkable finding since NMDAR bearing the GluN2A 
receptor subunit is necessary for LTP induction (Paoletti et al., 2013). Accordingly, here we have 
shown that activity-dependent LTP in SPNs is blocked by antagonists acting on the GluN2A, but 
not GluN2B, NMDAR subunit. In line with these findings, our data rule out significant effects of α-
syn on currents mediated by GluN2B subunit of NMDAR and by AMPAR. Moreover, as evidenced 
by WB assay, α-syn is able to lower the synaptic localization of GluN2A NMDAR subunit in 
striatal slices without affecting levels of other subunits of ionotropic glutamate receptors.
Alpha-synuclein alters NMDAR-mediated excitatory transmission at SPNs of both direct and 
indirect pathways 
According to the classical view, striato-nigral SPNs express D1-like DA receptors, representing the 
direct pathway of the basal ganglia, while striato-pallidal SPNs express the D2-like DA receptors, 
representing neurons of the indirect pathway (Gerfen et al., 1990; Gerfen and Surmeier, 2011). This 
differential molecular expression of DA receptors is important for two functional reasons. Firstly, 
activation of D1 DA receptor signalling is required for LTP (Reynolds et al., 2001; Calabresi et al., 
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2007), while D2 DA receptors are mainly implicated in LTD (Kreitzer and Malenka, 2007; Shen et 
al., 2008). The second aspect regards their possible different role in the motor function. In fact, 
activation of the direct pathway by DA is thought to promote movement initiation, whereas the 
activation of the indirect pathway would be involved in inhibition of motor activity (Mink, 2003; 
Nambu, 2008; Gerfen and Surmeier, 2011). In apparent contrast with this dichotomous view, more 
recent studies propose a new vision of the basal ganglia functionality, based on signalling 
integration at different levels (Cui et al., 2013; Calabresi et al., 2014). Anatomical evidences 
reported the existence of “bridging collaterals”, axon collaterals connecting neurons of the direct 
and indirect pathways (Cazorla et al., 2015). On the basis of these different theories, using striatal 
slices from dtTomato mice, we investigated whether the alteration of LTP caused by α-syn occurs 
either in a single or in both sub-populations of SPNs. We found that the detrimental effect of α-syn 
on LTP and on NMDAR synaptic currents is evident both in D1- and D2-expressing SPNs. 
Cortico-striatal and thalamo-striatal glutamatergic inputs are equally affected by alpha-
synuclein
Further evidence of the widespread toxic effect of α-syn on striatal synapses come from our 
investigation of the NMDAR-mediated current in cortico-striatal and in thalamo-striatal pathways. 
The striatum receives glutamatergic inputs both from cerebral cortex and thalamus (McGeorge and 
Faull, 1989; Smith et al., 2004; Doig et al., 2010) and these two systems act in concert to regulate 
motor function differentially contributing to specific tasks. Cortical afferents projecting to the 
dorsal striatum are mainly involved in planning, learning and execution of motor behaviour (Jog et 
al., 1999), whereas the thalamo-striatal inputs modulate attention-related stimuli, being engaged in 
behavioural switching, reinforcement functions and attention set-shifting (Smith et al., 2011). 
Moreover, these two systems might differentially contribute, in Parkinson’s disease patients, to the 
generation of glutamatergic dysfunction in the striatum. Thus, we have investigated a possible 
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differential effect of α-syn on cortico-striatal versus thalamo-striatal synapses. To this aim we used 
a distinct optical stimulation of the two pathways using para-horizontal brain slices. Compared to 
coronal slices, this particular tissue preparation allows to specifically discriminating the two 
projections converging on SPNs (Smeal et al., 2007). Interestingly, α-syn caused a similar reduction 
of GluN2A NMDAR current evoked by selectively activating either cortical or thalamic fibres. This 
finding, together with previous experiments performed with electrical stimulation, supports the idea 
that α-syn causes a widespread alteration of excitatory synaptic transmission within the striatum.
The widespread striatal synaptic dysfunction can be prevented by antibodies against alpha-
synuclein
Several studies described the consequences of the application of Abs against α-syn, reporting 
improvement in intracellular α-syn aggregates clearing, reduction of α-syn fibrils propagation, 
together with attenuation of memory and neurodegenerative deficits (Spencer et al., 2017). In the 
attempt to clarify whether specific monoclonal Abs against α-syn exert protective effects over 
synaptic plasticity, we employed Syn211 Ab and SynO2 Ab; both Abs recognizing all forms of 
human α-syn, however, SynO2 Ab is much more potent than Syn211 Ab in binding α-syn 
oligomers and fibrils (Giasson et al., 2000; Majbour et al., 2016). The depletion experiment we 
performed, confirmed that either Syn211 Ab or SynO2 Ab shows affinity for α-syn oligomeric 
aggregates, with a different binding specificity between the two Abs.  Interestingly, we found that, 
an overlapping dose-response effect of the two Abs in rescuing the LTP impairment induced by α-
syn in striatal SPNs. The two Abs also prevented the reduction of GluN2A expression levels caused 
by α-syn. This protective effect is consistent with our observation that α-syn alters LTP affecting 
NMDAR-mediated currents, in particular the GluN2A subunit. Interestingly, the PFF preparation 
injected intrastriatally in in vivo experiments contained both OLIGO and PFF aggregates. 
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Differential effect of fibrillar versus oligomeric forms of alpha-synuclein on visuo-spatial 
learning
Accumulating in vivo evidence showed that α-syn protofibrils directly injected in the striatum lead 
to a time-dependent spreading all over the brain accompanied by neuronal loss and motor deficits in 
mice within 9 months after the injection (Luk et al., 2012). In this study we aimed at verifying 
whether the pathological interaction between α-syn aggregates and NMDA receptors in the striatum 
led to impaired behavioural function; for this reason, we focused on an early time point when the 
aggregates remained localized within the striatum. To dissect the behavioural effects of α-syn 
aggregates we used a visuo-spatial learning task that we have previously shown to rely on NMDA 
receptors activation in the dorsal striatum (De Leonibus et al., 2003; De Leonibus et al., 2005).  α-
syn PFF injected rats show impaired spatial novelty detection, although they normally explore the 
objects during the habituation phase and can discriminate a new object among familiar ones. 
Interestingly, the intrastriatal injection of oligomers mimics the behavioural effects produced by 
PFF. This effect is even more severe than that one induced by PFF injection since while fibrils only 
affect the ability to discriminate the object displacement, oligomers impair both spatial and object 
novelty recognition. This is surprising considering that the PFF preparation injected intrastriatally in 
in vivo experiments contained both OLIGO and PFF aggregates and that the α-syn cocktail 
producing the rapid synaptic and plastic alterations mainly contain oligomeric/monomeric forms, 
but little or no fibrils, as confirmed by the ThT analyses. 
While the effect of in vivo injection of α-syn on SPN NMDAR currents does not provide a direct 
mechanistic explanation that NMDAR changes are responsible of the described behavioural 
alteration, it confirms that α-syn is able to produce molecular changes affecting the function of this 
receptor with possible behavioural consequences.
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Our experiments in α-syn-injected rats showed specific deficits in visuo-spatial exploration while 
locomotor activity was not affected respect to control animals. It possible that we failed to detect 
motor deficits because of the site and/or size of the injection within the striatum.  
All together, these findings suggest that oligomeric α-syn itself is harmful for synaptic plasticity and 
behavioural functions of the dorsal striatum. We speculate that further α-syn aggregation into 
protofibrils might limit their direct impact within the area of injection, while favouring their 
spreading across brain regions as previously reported (Luk et al., 2012). Further studies are 
necessary to address this issue. The translational relevance of this preclinical data for PD are 
evidenced by findings in humans showing visuo-spatial learning deficit in de novo PD patients 
showing spatial location deficits (Pillon et al., 1997). 
Conclusions
Although the role of α-syn in the pathogenesis of Parkinson’s disease has been deeply investigated, 
little is known on the effect of α-syn on striatal synaptic transmission and related early behavioural 
alterations. Our research demonstrates a widespread and NMDAR-related dysfunction of striatal 
synaptic network induced by α-syn. We report for the first time that α-syn, through interaction with 
GluN2A-bearing NMDAR, impairs LTP in SPNs of the direct and indirect basal ganglia pathways 
and causes visuo-spatial learning deficit. The α-syn-induced synaptopathy is also observed when 
neurons are optogenetically activated by either cortical or thalamic inputs. Notably, both plastic and 
behavioural alterations observed in our study do not seem to be dependent on dopaminergic 
degeneration. In fact, the plastic dysfunctions induced by acute in vitro application of α-syn are not 
rescued by exogenous DA. Accordingly, the observed visuo-spatial learning deficits are not 
associated with a loss of dopaminergic terminals. Moreover, the open field analysis does not show 
overt motor impairment indicating that our in vivo model recapitulates an early stage of the disease.
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Finally, we provide evidence that antibodies neutralizing α-syn are effective in blocking its 
detrimental actions. Taken together these data support the use of antibodies against α-syn as a valid 
approach to preserve the functionality of synaptic plasticity in the striatal network.
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Figure legends
Figure 1. Effect of α-synuclein on the intrinsic membrane properties and synaptic plasticity of 
striatal SPNs. (A) Representative voltage traces (top) and current-voltage graph (bottom) recorded 
from SPNs during the injection of hyperpolarizing and depolarizing steps of current in control 
conditions (n=5) and in the presence of 30 nM α-syn (n=4) show no differences in the firing pattern 
discharge and intrinsic membrane properties of these neurons. (B) Examples traces (top) and time 
course (bottom) of the excitatory postsynaptic currents (EPSCs) measured before and 30 minutes 
after the application of the HFS protocol show no differences in the LTD induction in SPNs 
recorded from control slices (n=6) and from slices incubated with α-syn (n=6). (C) Paired EPSC 
traces (top) and time-course graph of the EPSC amplitude (bottom) recorded in SPNs from control 
slices (n=7) and in SPNs of slices incubated with 30 nM α-syn (n=7) before and after the delivery of 
the HFS protocol show the block of LTP in SPNs recorded from slices treated with α-syn. (D) 
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Histogram showing the EPSC amplitude 30 min following the HFS protocol of SPNs recorded from 
control striatal slices and from slices incubated with increasing concentrations of α-syn (3 nM, n=6, 
10 nM, n=7, 300 nM, n=6). (E) EPSC traces (top) and time-course graph of the EPSC amplitude 
(bottom) measured in SPNs of control slices (n=7) and of slices incubated with 30 nM α-syn in the 
presence of 30 μM dopamine (DA) (n=6) bath applied before and after the HFS protocol. Data are 
represented as mean ± SEM. (F) Histogram of the ELISA shows time- and dose-dependent α-syn 
oligomers; higher level of α-syn oligomers were detected in the 300 nM α-syn samples collected at 
30 min. (G) ThT assay shows that little fluorescence was detected with the 30 nM concentration, 
independently on the timing of sampling. In contrast, high fluorescence signal was measurable with 
the 300 nM dose. Data are reported as percentage of fluorescence registered at T0 ± SEM. *P<0.05, 
**P<0.01, ***P<0.001.
Figure 2. Effect of alpha-synuclein on AMPAR- and NMDAR-mediated currents. (A) Example 
traces (top) and histogram (bottom) showing the AMPAR-mediated synaptic current of SPNs 
recorded in pharmacological isolation, in the presence of APV and picrotoxin, before and after the 
application of 30 nM α-syn (n=6). (B) Example traces of EPSCs (top) evoked at +40 and -80 mV 
holding potential and histogram (bottom) showing the AMPAR RI of SPNs recorded in control 
conditions and in the presence of α-syn (n=6). (C) Histogram showing the averaged EPSC 
amplitude carried by the GluN2A-expressing NMDAR measured in SPNs in the presence of 
picrotoxin, CNQX and ifenprodil (open orange bar) and after subsequent addition of 30 nM α-syn 
(n=6) (filled cyan bar). The superimposed traces show EPSCs acquired at +40 mV holding potential 
of a SPN in the presence of picrotoxin + CNQX (black trace), picrotoxin + CNQX + ifenprodil 
(orange trace) and picrotoxin + CNQX + ifenprodil + α-syn (cyan trace). (D, E) Histograms 
showing the averaged EPSC amplitudes carried by the GluN2B-expressing NMDAR measured in 
SPNs in the presence of picrotoxin, CNQX and NVP-AAM077 (n=6) (D, open violet bar) or 
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picrotoxin, CNQX and TCN-201 (n=6) (E, open violet bar) and in the presence of 30 nM α-syn on 
this current (n=6) (D-E, filled cyan bars). Superimposed traces showing EPSCs acquired from a 
single SPN following the application of picrotoxin + CNQX (D, black trace), picrotoxin + CNQX + 
NVP-AAM077 (D, violet trace), picrotoxin + CNQX + NVP-AAM077 + α-syn (D, cyan trace) or 
picrotoxin + CNQX (E, black trace), picrotoxin + CNQX + TCN-201 (E, violet trace), picrotoxin + 
CNQX + TCN-201 + α-syn (E, cyan trace). (F, G) Representative WB images and histograms 
showing the effects of incubation (1 hour) of corticostriatal slices with 30 nM α-syn on the synaptic 
localization of GluA1 and GluA2 AMPAR subunits (n=8) (F) and GluN2A and GluN2B NMDAR 
subunits (n=6) (G). Data are normalized against tubulin and are shown in the graph as mean ± SEM. 
*P<0.05, **P<0.01.
Figure 3. Effect of alpha-synuclein on SPNs of the direct and indirect basal ganglia pathway. 
(A) Images of three regions acquired from a striatal slice of a transgenic Drd1a-tdTomato mouse 
showing fluorescent D1R-positive neurons (left, in red pseudocolor and top right) and a non-
fluorescent (putative D2R-positive) SPN (bottom right). (B) Example traces and time-course graph 
showing the LTP induced in both fluorescent (n=6) and non-fluorescent (n=6) SPNs after the 
delivery of the HFS protocol. (C, D) EPSC pairs (top) and time-courses graphs of the EPSC 
amplitude (bottom) showing that α-syn is able to block the LTP in both D1R-positive (n=5) (C) and 
putative D2R-positive SPNs (n=5) (D) following the HFS protocol. (E, F) Histograms showing the 
mean EPSC amplitudes of the NMDAR-mediated synaptic currents measured in pharmacological 
isolation in D1R-positive (n=6) (E) and in putative D2R-positive SPNs (n=4) (F) both in control 
condition and after the application of 30 nM α-syn. The superimposed traces show EPSCs acquired 
from a D1R-positive SPN (E) and putative D2R-positive SPN (F) in the presence of CNQX plus 
picrotoxin and in CNQX plus picrotoxin plus α-syn. Note that α-syn is able to reduce the NMDAR-
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mediated current in a similar manner in these neuronal sub-populations. Data are represented as 
mean ± SEM. * P<0.05, **P<0.01.
Figure 4. Effect of alpha-synuclein on SPNs activated by optical stimulation of cortico-striatal 
and thalamo-striatal glutamatergic afferents. (A) Representative para-horizontal brain slice 
including cortical, striatal and thalamic regions and (B) scheme of a para-horizontal slice showing 
the regions of the cortex and the thalamus where optical stimulation can activate glutamatergic 
afferents to SPNs recorded in the striatum. (C, F) Histograms of the SPNs mean NMDA-EPSC 
amplitudes optically stimulated in the cortex (C) or in the thalamus (F) in the presence of 3 µM 
ifenprodil to isolate the GluN2A-EPSC (n=6 cortex, n=5 thalamus) (orange open bar) or in the 
presence of 10 µM TCN-201 (n=6) to isolate the GluN2B-EPSC (violet open bar). Data are 
presented as percentage of the control NMDAR-EPSCs recorded in the presence of picrotoxin and 
CNQX (dotted line). (D, G) Histograms of the averaged GluN2A- and GluN2B-EPSC amplitudes 
optically stimulated in the cortex (D) or in the thalamus (G) measured in SPNs in the presence of 
picrotoxin, CNQX, ifenprodil (orange outlined bars) without (n=6) and with 30 nM α-syn (orange 
outlined, cyan filled bar) and picrotoxin, CNQX, TCN-201 (violet outlined bars) without (n=6) and 
with 30 nM α-syn (violet outlined, cyan filled bar). α-syn (n=4-6) is applied for 2, 5 and 10 min. 
Data are presented as percentage of the control GluN2A- and GluN2B-EPSCs. (E, H) Top, 
superimposed EPSCs evoked by optical stimulation of the cortex (E) or the thalamus (H) acquired 
from a SPN in the presence of picrotoxin, CNQX, ifenprodil (orange trace) and after further the 
application of 30 nM α-syn (cyan trace). Bottom, EPSCs acquired from a SPN in the presence of 
picrotoxin, CNQX, TCN-201 (violet trace) and after further the application of 30 nM α-syn (cyan 
trace). Note that α-syn significantly reduces the GluN2A- but not GluN2B-EPSC. Data are 
represented as mean ± SEM. **P<0.01, ***P<0.001.
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Figure 5. Action of monoclonal antibodies against α-synuclein on SPNs synaptic plasticity. (A) 
Time-course graph showing the EPSC amplitudes of SPNs recorded before and after the LTP 
induction by HFS in slices incubated for 1 hour with 30 nM α-syn and in slices treated with Syn211 
Ab (1:10) alone (n=7) or with Syn211 Ab (1:10) plus α-syn (n=7). (B) Time-course of the SPNs 
EPSC amplitudes recorded before and after the HFS protocol in slices treated with α-syn and in 
SPNs in the presence of SynO2 Ab alone (1:10.000) (n=7) or SynO2 Ab (1:10.000) plus α-syn 
(n=7). Note that the treatment with Syn211 or SynO2 Abs is able to restore the LTP in the presence 
of α-syn. (C) Immunoprecipitation experiment with the samples collected at time 0 and 30 min with 
antibodies (SynO2 or Syn211) estimates the α-syn oligomers left in the sample using oligomeric 
ELISA. (D, E) WB analysis for GluN2A subunit of the NMDAR in the postsynaptic fraction (TIF) 
obtained from striatal slices incubated with α-syn alone (30 nM) or with α-syn plus Syn211 (1:10) 
or Syn-O2 (1:10.000) antibodies and control slices. α-syn reduced GluN2A localization at 
postsynaptic sites, while treatment with two different anti-α-syn antibodies was able to rescue 
GluN2A levels in the TIF. Data are normalized against tubulin and are shown in the graph as mean 
± SEM. *P<0.05, **P<0.01.
Figure 6. Intra-striatal PFF alpha-synuclein injection. (A) Representative TEM image of 
preformed fibrils (PFF) preparation injected in rat striatum. (B, C) Representative brain slice of 
animals injected with α-syn in the striatum. Immunofluorescence for α-syn and phospho-Ser129-hu-
α-Syn. High levels of phosphor-Ser129-hu-α-Syn are detectable at the injection site within the 
striatum, with no spreading in the surrounding brain regions. (B) A higher magnification (60x) 
evidences the α-syn aggregates positive for phospho-Ser129hu-α-Syn. (B) Representative brain 
slice of animals injected with PBS in the striatum. No positive staining of phospho-Ser129-hu-α-
Syn is detectable in the striatum of the control group at low and high magnification (C).
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Figure 7. Behavioural and electrophysiological alterations in rats injected with human alpha-
synuclein. (A) Schematic representation of the visuo-spatial novelty reaction task. Rats were 
habituated to the empty arena (S1). During the habituation phase they were allowed to explore for 6 
consecutive sessions (S2-S7) three different objects kept in constant position. Spatial learning was 
tested by displacing the position of two objects, the blu one (Displaced object-DO), and comparing 
its relative preference as compared to the non-displaced objects (NDO), the black and the purple 
once (S8). Animals were given a further session to habituate to the spatial change (S9). During the 
last session object learning was tested by substituting one of the three objects (the blu one, 
substituted object-SO) with a new one (orange), and the other two objects with identical copies, to 
avoid the use of olfactory cues for object recognition (non-substituted objects-NSO) (S10). (B) 
Histograms showing the mean time (s) objects exploration during the habituation phase by control 
and α-syn rats (left panel); Re-exploration index of displaced DO and NDO objects after the spatial 
change, showing that control, but not α-syn rats, prefer DO vs. NDO (center panel); Re-exploration 
index of substituted SO and NSO objects after the object change, showing that both control and α-
syn rats preferred SO vs. NSO (right panel). *P<0.05 DO/SO vs. NDO/NSO, within group; # 
P<0.05 α-syn vs. control, Duncan post-hoc test. DO: displaced objects; NDO: non-displaced 
objects; SO: substituted object; NSO: non-substituted object. Control rats, n=9, α-syn rats, n=8. (C) 
Histogram showing the NMDA/AMPA ratio measured in SPNs of α-syn- (n=5) and of sham-
injected (control) rats (n=5). Traces showing an EPSC measured at +40 mV and -80 mV holding 
potential in a SPN of a control and α-syn rat. (D) Histogram showing the NMDA-current amplitude 
of SPNs from α-syn- (n=5) and control rats (n=5) before (dashed line) and after the application of 
ifenprodil to isolate the GluN2A-mediated NMDA-current. Traces showing an EPSC measured at 
+40 mV holding potential in a SPN of a control and α-syn rat before and after the application of 
ifenprodil. * P<0.05, ** P<0.01   
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Figure 8. Intra-striatal oligomeric alpha-synuclein injection and behavioural alterations. (A) 
Representative TEM image of OLIGO α-syn preparation injected in rat striatum showing a majority 
of small oligomers with very few protofibrils. (B-C) Representative images of animals injected with 
α-syn in the striatum. Immunofluorescence for hu-α-syn (B) and phospho-Ser129-hu-α-Syn (C). 
40x magnification images evidences that high levels of hu-α-syn (B) and phosphor-Ser129-hu-α-
Syn (C) are detectable within the striatum. Representative images of animals injected with PBS in 
the striatum (B, C). No positive staining of phospho-Ser129-hu-α-Syn (C) is detectable in the 
striatum of the control group at 40x magnification. Arrows indicate hu-α-syn and phospho-Ser129-
hu-α-Syn positive cells; scale bars: 50 m. (D-F) Histograms showing the mean time (s) objects 
exploration during the habituation phase by control and oligomeric α-syn rats. Re-exploration index 
of displaced DO and NDO objects after the spatial change, showing that control, but not α-syn rats, 
prefer DO vs. NDO (center panel). Re-exploration index of substituted SO and NSO objects after 
the object change, showing that both control and α-syn rats preferred SO vs. NSO (right panel). 
Control rats, n=6, oligomeric α-syn rats, n=6. *P<0.05 DO/SO vs. NDO/NSO, within group, 
Duncan post-hoc test. DO: displaced objects; NDO: non-displaced objects; SO: substituted object; 
NSO: non-substituted object.  
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Parkinson’s disease is a progressive neurodegenerative disorder characterized by altered striatal 
dopaminergic signalling that leads to motor and cognitive deficits. Parkinson’s disease is also 
characterized by abnormal presence of soluble toxic forms of alpha-synuclein (α-syn) that, when 
clustered into Lewy bodies, represents one of the pathological hallmark of the disease. However, 
also α-syn oligomers might directly affect synaptic transmission and plasticity in Parkinson’s 
disease models. Accordingly, by combining electrophysiological, optogenetic, 
immunofluorescence, molecular and behavioural analyses, here we report that α-syn reduces N-
methyl-D-aspartate (NMDA) receptor-mediated synaptic currents and impairs corticostriatal long-
term potentiation (LTP) of striatal spiny projection neurons (SPNs), of both direct (D1-positive) and 
indirect (putative D2-positive) pathways. Intrastriatal injections of α-syn produce deficits in visuo-
spatial learning associated with reduced function of GluN2A NMDA receptor subunit indicating 
that this protein selectively targets this subunit both in vitro and ex vivo. Interestingly, this effect is 
observed in SPNs activated by optical stimulation of either cortical or thalamic glutamatergic 
afferents. We also found that treatment of striatal slices with antibodies targeting α-syn prevents the 
α-syn-induced loss of LTP and the reduced synaptic localization of GluN2A NMDA receptor 
subunit suggesting that this strategy might counteract synaptic dysfunction occurring in Parkinson’s 
disease.
KEYWORDS: Dopamine; Glutamate; Long-term potentiation; Monoclonal antibodies; Oligomers; 
Optogenetics; Parkinson’s disease; Synaptic plasticity; Striatum.
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Alpha-synuclein (α-syn) is a 140 amino acids presynaptic protein causally involved in the 
pathogenesis of Parkinson’s Disease (Spillantini and Goedert, 2016). The main mechanisms of α-
syn-mediated cellular damage involve mitochondrial function, endoplasmic reticulum-Golgi 
trafficking, calcium ions influx through formation of pore-like structures, proteins degradation and 
oxidative stress (Gallegos et al., 2015; Wong and Krainc, 2017). 
The protein exists as unstructured monomer widely distributed in the central nervous system and is 
involved in the regulation of presynaptic vesicle pool, neurotransmitter release, synaptic function 
and plasticity (Abeliovich et al., 2000; Cabin et al., 2002). However, α-syn monomers have the 
intrinsic tendency to aggregate in structures of higher molecular weights (Gallegos et al., 2015) and 
in particular conditions, such as pH variations, oxidative stress, mutations and overexpression of α-
syn gene. This process can lead to the formation of α-syn oligomers, protofibrils and eventually 
fibrils, the main components of Lewy Bodies (LBs) (Spillantini et al., 1997; Wong and Krainc, 
2017). While LBs represent a neuropathological hallmark of Parkinson’s disease and the 
histological sign of synucleinopathies, they show no actual direct neurotoxic properties (Tanaka et 
al., 2004). Mechanisms mediating α-syn toxicity in humans have not been determined yet, however, 
several studies point to α-syn oligomers and to protofibrils as major players in synaptic dysfunction 
(Diogenes et al., 2012; Rockenstein et al., 2014). 
The striatum, a subcortical nucleus receiving major excitatory inputs from the cortex and the 
thalamus (Ding et al., 2008), is a brain region particularly involved in Parkinson’s disease and 
oligomeric forms of α-syn may affect synaptic transmission and long-term synaptic plasticity in this 
structure, leading to the motor and behavioural deficits observed in Parkinson’s disease (Tozzi et 
al., 2016). 
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Although in Parkinson’s disease models pathological changes in synaptic plasticity have been 
widely reported in vivo as well as in vitro (Calabresi et al., 2014), at present, no data are available 
on the effects of α-syn on synaptic transmission and synaptic plasticity of striatal spiny projection 
neurons (SPNs) and their possible underlying mechanisms. 
SPNs are GABAergic output neurons, which represent the large majority of neuronal population in 
the striatum (Calabresi et al., 2014). They express a peculiar NMDA subunit receptor composition 
including GluN2A and GluN2B subunits (Dunah et al., 2000; Gardoni et al., 2006), whose distinct 
activation regulates glutamatergic inputs in striatal SPNs. In fact, the selective pharmacological 
modulation of these subunits differentially alters amplitude and kinetics of NMDARs responses 
also affecting responses to dopaminergic modulation (Jocoy et al., 2011; Vastagh et al., 2012). 
Moreover, an unbalanced GluN2A/GluN2B subunit ratio of the striatal synaptic NMDAR is a key 
element in the regulation of motor behaviour and synaptic plasticity in Parkinson’s disease 
(Mellone et al., 2015).
For this reason, it is of great importance to assess whether α-syn could alter synaptic transmission 
and plasticity in striatal SPNs by interfering with different NMDAR subunits. 
In the present study, by utilizing a multidisciplinary approach including electrophysiological, 
optogenetic, immunofluorescence and molecular techniques as well as behavioural testing, we have 
determined the pathological effects of α-syn on the striatal network controlled by NMDAR 
subunits.
Finally, we have provided the first proof of concept evidence that antibodies against α-syn can 
prevent these pathological synaptic dysfunctions.
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All experimental procedures were conducted in conformity with the European Directive 
2010/63/EU, in accordance with protocols approved by the Animal Care and Use Committee at the 
University of Perugia (Perugia, Italy) and IRCCS Fondazione Santa Lucia (Rome, Italy). 
Animals
For electrophysiological and behavioural experiments we used 2-3 month-old male Wistar rats 
(Charles River, Calco, Italy); 2 month-old transgenic male BAC Drd1a-tdTomato mice containing a 
mouse Drd1a promoter directing the expression of a modified DsRed fluorescent protein (B6.Cg-
Tg(Drd1a-tdTomato)6Calak/J, tdTomato, The Jackson Laboratory, Bar Harbor, Maine, U.S.A.) and 
B6.Cg-Tg(Thy1-COP4/EYFP)18Gfng/J transgenic mice (Thy1-ChR2-YFP) expressing the light-
activated ion channel Channelrhodopsin-2 (ChR2) fused to yellow fluorescent protein under the 
control of the mouse thymus cell antigen 1 (Thy1) promoter. Selective expression of ChR2 has been 
demonstrated both in cortical neurons of layer V and thalamic neurons (Arenkiel et al., 2007; Lim 
et al., 2012).
Animals were housed at 23°C room temperature with food and water ad libitum and a 12-hour 
light-dark cycle. All efforts were made to minimize the number of animals used and their suffering.
Electrophysiology
Coronal brain slices including the cortex and the striatum were cut from Wistar rats and tdTomato 
mice using a vibratome at 220-240 μm thickness. To better preserve the connectivity of thalamic 
fibres to the striatum, para-horizontal slices (250 μm) were cut from Thy1-ChR2-YFP mice for 
optogenetic experiments (Smeal et al., 2007; Ding et al., 2008; Sciamanna et al., 2012). Slices were 
maintained in a Kreb’s solution, bubbled with a 95% O2–5% CO2 gas mixture at room temperature 
containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 10 glucose, and 25 
NaHCO3 (Calabresi et al., 1992b). Single slices were transferred to a recording chamber and 
submerged in a continuously flowing Krebs’ (34 °C; 2.5–3 ml/minute) bubbled with a 95% O2–5% 
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CO2 gas mixture. The internal solution for path-clamp recordings contained (in mM): 145 K+-
gluconate, 0.1 CaCl2, 2 MgCl2, 0.1 EGTA, 10 HEPES, 0.3 Na-GTP and 2 Mg-ATP, adjusted to pH 
7.3 with KOH. For recording NMDAR-mediated currents, neurons were held at +40 mV membrane 
holding potential and the internal solution contained (in mM): 120 CsMeSO3, 10 CsCl, 8 NaCl, 2 
MgCl2, 10 HEPES, 0.2 EGTA, 10 TEA, 5 QX314, 0.3 Na-GTP and 2 Mg-ATP, adjusted to pH 7.3 
with CsOH. Only neurons identified as striatal SPNs were considered for the experiments. 
Normally, for each animal we obtained 2-3 experiments. SPNs were identified by their 
hyperpolarized resting membrane potential (RMP, ~-80 mV), absence of spontaneous action 
potential discharge and presence of tonic firing activity during current-induced membrane 
depolarization. Signals were amplified with a Multiclamp 700B amplifier (Molecular Devices), 
recorded and stored on PC using pClamp10. Whole-cell voltage-clamp recordings (access resistance 
15–30 MΩ; holding potential −80 mV) were performed with borosilicate pipettes (4–7 MΩ) filled 
with the standard internal solution. A bipolar electrode, connected to a stimulation unit (Grass 
Telefactor), was located in the white matter between the cortex and the striatum to stimulate 
glutamatergic fibres (0.1 Hz) and evoke excitatory post-synaptic currents (EPSCs), while the 
recording electrode was placed in the dorsolateral striatum. In all patch-clamp experiments 50 µM 
picrotoxin was added to the external medium to block GABAA receptors. To induce LTP or long-
term depression (LTD), a high-frequency stimulation (HFS) protocol consisting of three trains of 3 
seconds (20 seconds interval) was delivered at 100 Hz. During HFS protocol, the stimulus intensity 
was increased to supra-threshold levels. External Mg2+ ions were omitted to maximize the 
contribution of NMDARs during LTP experiments (Calabresi et al., 1992b). The AMPA receptor 
(AMPAR)- and NMDAR-mediated synaptic currents (AMPA-EPSCs and NMDA-EPSCs) were 
recorded in pharmacological isolation, with 50 µM picrotoxin plus 50 µM APV and 50 µM 
picrotoxin plus 10 µM CNQX, respectively. AMPAR rectification index (RI) was obtained by 
dividing the AMPA-EPSC amplitude measured at +40 mV by the one measured at -80 mV. 
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NMDA/AMPA ratios were calculated by dividing the NMDA-EPSC positive peak amplitude, 
acquired at +40 mM holding potential in the presence of 50 µM picrotoxin plus 10 µM CNQX, by 
the EPSC negative peak amplitude acquired at -80 mV in picrotoxin.
Optogenetic
Optical stimulation of cortex or thalamus was performed using an infinity cube (CAIRN Research, 
UK), consisting of a 470 nm filter system mounted on an Olympus BX-51WI microscope and 
controlled by an Optoflash (CAIRN Research, UK) LED light Switch. The experiments were 
performed on Thy1-ChR2-YFP mice. Light power at microscope objective exit was 2-30 mW/mm2. 
Spotlight was made by utilizing a diaphragm placed along the light path. Slices were illuminated 
from the top and a round spot was created with a radius of approximately 500-600 μm in order to 
avoid light spread to unwanted brain structures and delivered on the cortex or the thalamus. A 3 
mseconds light pulse was delivered every 15 seconds on cortical layer V or in the thalamus in order 
to evoke EPSCs in MSNs.
Preparation of alpha-synuclein in Krebs solution
Different concentrations of α-syn cocktail (3, 10, 30 and 300 nM) (referred in the text as α-syn 
OLIGO) were prepared in Krebs solution bubbled with a 95% O2-5% CO2 gas mixture at room. The 
solutions were incubated up to 1 hour taking aliquots at different time points.
Alpha-synuclein preformed fibrils (PFF) preparation
Lyophilized fresh monomeric α-syn (0.33 mg) (recombinant human α-syn) was dissolved in sterile 
PBS to a final concentration of 1 mg/mL (≈70 µM). 300 µL α-syn-containing buffer has been 
incubated for 7 consecutive days at 37 °C on a shaker (300 rpm) in a sterile 96-well plate. At the 
end of this procedure the α-syn PFF aliquots were stored at -80 °C until the use for intra-brain 
injection. 
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Transmission electron microscopy (TEM)
The samples (5 l) were deposited on a glow-discharged Formvar-Carbon 300-mesh coated copper 
grid (Agar Scientific, UK) for 2 minutes, blotted with Whatman filter paper and negatively stained 
with 2% uranyl acetate for few seconds.  Grids were examined with an Energy Filtering 
transmission electron microscope Leo 912 ab (Zeiss, Germany) operating at 100KV and digital 
images were acquired by a CCD camera (Proscan, Germany) 1kx1k with the iTEM software 
(Olympus, Germany).
Detection of alpha-synuclein oligomers in the Krebs solution
A 384-well ELISA microplate (Nunc MaxiSorb, Nunc) was coated by overnight incubation at 4 °C 
with SynO2 (0.2 μg/ml) in 200 mM NaHCO3, pH 9.6 (50 μl/well). The plate was then washed with 
PBST and incubated with 100 μl/well of blocking buffer for 2-hours at 37 °C. After washing, 50 μl 
of the samples (1 nM) was added to each well, and plates were incubated at 37 °C for 2.5-hours. 
FL-140 (rabbit polyclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted in 
blocking buffer at 1:1 K, was added to the appropriate wells, and incubated at 37 °C for 2 h. Next, 
the plate was washed and incubated for 2 h at 37 °C with 50 μl/well of goat anti-rabbit IgG HRP 
(Jackson ImmunoResearch) diluted in blocking buffer (1:15 K). After washing, the plate was 
incubated with 50 μl/well of an enhanced chemiluminescent substrate (SuperSignal ELISA Femto, 
Pierce Biotechnology, Rockford, IL). The chemiluminescence, expressed in relative light units, was 
immediately measured using VICTOR™  X3 multilabel plate reader (PerkinElmer). 
Thioflavin T binding assay
The formation of α-syn oligomers was confirmed by Thioflavin T (ThT) binding assay (Nilsson, 
2004). ThT was incubated at a final concentration of 20 µM in different α-syn solutions (30 nM and 
300 nM, respectively) collected at T0 and after 60 minutes of incubation in Krebs solution bubbled 
with a 95% O2-5% CO2 gas mixture at room temperature. Emission wavelength scan was performed 
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with an excitation wavelength of 450 nm using a plate reader (BMG Labtech Clariostar). The assay 
was performed in triplicate. 
Immunoprecipitation of alpha-synuclein oligomers formed in Krebs solution
500 μl of the samples collected at time points 0 and 30 minutes were incubated with 0.043 and 4.3 
X 10-5 μg/ml of either SynO2 or Syn211 antibodies for 2-hours at room temperature. 100 μl of 
protein G beads was added and incubated for 1-hour at room temperature. The samples were 
centrifuged and the supernatant were collected and checked for the presence of α-syn oligomers by 
ELISA. The bound α-syn oligomers form the beads were eluted by adding 50 μl of 0.2 M glycine 
pH 2.5 and immediately neutralized with 5 μl of 1 M Tris pH 8.0 and taken for western blot 
analysis.
Subcellular fractionation
For the extraction of triton-insoluble postsynaptic fraction (TIF), striatal areas were carefully 
isolated and collected on dry ice from control slices and slices treated with α-syn alone (30 nM) and 
with Abs against α-syn (Syn211 and SynO2). Striatal areas were then homogenized with a Teflon-
glass potter in ice-cold buffer containing (in mM) 320 sucrose, 1 Hepes, 1 MgCl2, 1 NaHCO3, 0.1 
phenylmethylsulfonylfluoride at pH 7.4 in the presence of CompleteTM Protease Inhibitor Cocktail 
Tablets (Roche Diagnostics, Basel, Switzerland) and phosSTOPTM Phosphatase Inhibitor (Roche 
Diagnostics). The sample was spun at 13.000 g x 15 minutes at 4 °C. The resulting pellet was 
resuspended in Triton-KCl buffer (0.5% Triton X-100 and 150 mM KCl) and, after 15 minutes 
incubation on ice, it was spun further at 100.000 g x 1-hour at 4 °C. The pellet (triton-insoluble 
postsynaptic fraction, TIF) was resuspended in 20 mM Hepes buffer supplemented with 
CompleteTM Protease Inhibitor Cocktail Tablets and stored at -80 °C. 
Western blotting (WB)
The levels of NMDARs and AMPARs in the TIF were analysed by WB. TIF samples were 
separated onto a 7% acrylamide/bis acrylamide gel. Proteins were blotted onto a nitrocellulose 
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membrane (Bio-Rad, Hercules, CA, USA) and probed with the appropriate primary antibodies 
followed by the corresponding HRP-conjugated secondary antibodies. Labeling detection was 
performed with ChemiDoc MP Imaging System (Bio-Rad) and images were acquired with 
ImageLab software (Bio-Rad). The primary antibodies used in this study are anti-GluN2A 1:500 
(Sigma-Aldrich, St. Louis, MO, USA), anti-GluN2B 1:500 (Neuromab, Davis, CA, USA), anti-
GluA1 1:1000 (Neuromab), anti-GluA2 1:500 (Neuromab) and anti-tubulin 1:20000 (Sigma-
Aldrich). The latter was always used as loading control for normalization. 
Immunolabeling
Primary antibodies of hu-α-Syn (1:1000, sc-12767, Santa Cruz Biotechnology) in combination with 
hu-α-Syn phosphorylated on Ser129 (hu-α-Syn-phospho S129, ab51253; abcam) or in combination 
with tyrosine hydroxylase (TH 1:500, AB152; Merck Millipore) were used. 30 µm coronal slices, 
obtained with the use of a vibratome (Leica VT1000 S) were incubated overnight at 4 °C with a 
PBS solution containing BSA 0.1% and the combination of two primary antibodies. After rinsing in 
PBS, the sections were incubated for 2-hours with a mixture of secondary antibodies: goat anti-
rabbit Alexa Fluor 647, goat anti-mouse Alexa Fluor 488 (1:300; AP187SA6 and AP124JA, Merck 
Millipore). After subsequent washes in PBS, brain slices were incubated with DAPI (S7113; Merck 
Millipore) for 10 minutes and finally mounted on gelatin-coated slides and coverslipped. The 
specificity of immunoreaction was controlled by omitting primary antibodies. Images of the medial 
and lateral striatum (60x magnification) were taken using a fully motorized confocal microscope 
Nikon A1 and Nikon NIS Elements Advanced Research software. 
Surgery 
A total of 30 male Wistar rats (Charles River, Italy) were housed three x cage with free access to 
chow and water under a 12:12 h light–dark cycle. All surgical operations were performed under 
ketamine/xylazine anaesthesia. Animals received two bilateral intrastriatal injections of either α-syn 
PFF (n=9), OLIGO (n=6) or PBS (control, n=15). The volume injected using a 10 μl Hamilton 
Page 53 of 101




microsyringe was 1 μl for each site. The injection rate was 0.38 μl/minute and for each site the 
cannula was left in place for additional 2 min before retracting it. The coordinates, based on a 
previous study using these parameters to perform striatal lesions (Kirik et al., 1998), were the 
following: 1) anteroposterior (AP) +1.0; mediolateral (ML) +3.0; dorsoventral (DV) -5.0; 2) AP 
+1.0; ML -3.0; DV -5.0. ML coordinates were taken from lambda, AP coordinates were from 
bregma, according to Paxinos and Watson (Paxinos, 2005). Tooth bar was set at 0.00. After the 
surgery the animals were monitored until awake and then brought back to animal facility. Six weeks 
after the surgery the animals were tested for motor behaviour and cognition deficit.
Visuo-Spatial Memory Task
Visuo-Spatial Memory Task was a rat adapted version of the visuo-spatial memory task previously 
described in mouse (De Leonibus et al., 2007; De Leonibus et al., 2009; Rodo et al., 2017). The test 
was divided in 10 sessions of 5 minute each. The interval between the sessions was 3 minutes. 
Briefly, during session 1 (S1), rats were placed in an empty a square open field to habituate to the 
context (60x60 cm).  After this, from session 2 to session 7 (S2-S7), rats were free to explore three 
objects positioned in the arena to allow them to learn information about the objects and their spatial 
location in the arena (habituation phase). To test whether the animals learned spatial information 
related to the position of the objects, during the spatial test session 8 (S8), the objects configuration 
was changed by moving one object (the displaced object, DO) and leaving the other two objects in 
the same position (non-displaced objects, NDO1 and NDO2). In session 9 (S9), the configuration of 
the objects was kept unchanged to let the animal to habituate to the spatial change. In the last 
session (S10), to test whether animals learned information about the shape of the object, one of the 
familiar objects was replaced by a new one (substituted object, SO); the other two objects were left 
unchanged (non-substituted objects, NSO1 and NSO2). Object exploration was defined as the time 
in which the nose of the animal was in directed toward the object (<2 cm distance). The animals’ 
ability to selectively react to the spatial change was analysed by calculating the spatial exploration 
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index (DO=DO [S8]−DO [S7]; NDO=NDO [S8]−NDO [S7]), while the animals’ ability to 
selectively react to the non-spatial change (novel object) was analysed by calculating non-spatial 
exploration index (SO=SO [S10]−SO [S9]; NSO=NSO [S10]−NSO [S9]). Basal motor activity was 
evaluated during S1, by measuring time interval changes in distance travelled (cm), immobility time 
(seconds) and maximal speed (cm/second). 
Statistical Analysis
Data analysis of electrophysiological experiments was performed off-line using Clampfit10 
(Molecular Devices) and GraphPad Prism 5.0 (GraphPad Software). Values in the text and figures 
are mean ± standard error of the mean (SEM), n representing the number of recorded neurons. 
Changes of EPSC amplitude induced by drugs or by stimulation protocols were expressed as a 
percentage of the baseline, the latter representing the normalized EPSC mean amplitude acquired 
during a stable period (10–15 minutes) before delivering drugs or stimulation and statistically 
evaluated by the Student’s t-test for unpaired samples. LTP and LTD presence were statistically 
verified with the Student’s t-test for paired samples by comparing in each experiment values of the 
EPSC amplitudes at 25–30 minutes after the application of the HFS protocol relatively to the 
baseline. Current-voltage (I-V) curves were compared using the two-way ANOVA. The 
significance level was established at P<0.05. For WB experiments, significance of the differences 
was determined by one-way ANOVA followed by Tukey’s post-hoc test or by unpaired Student’s t-
test as appropriate. For ThT binding assay significance of the differences was determined by 
Student’s t-test. For behavioural analysis, data were analysed by using two-way Analysis of 
Variance (ANOVA) for repeated measure, with treatment (two levels: control and α-syn) as 
between factor. Duncan post hoc analysis was used when appropriate. 
When parametric tests were used, normality was checked with Shapiro-Wilk test and visual 
inspection of data distribution. The criterion for significance was set at P<0.05. We used Shapiro-
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Wilk test for its level of power compared to other procedures in small sample size scenarios 
(Royston, 1993).
Drugs
Picrotoxin, D-(-)2-amino-5-phosphonopentanoic acid (APV), 6-cyano-7- nitroquinoxaline-2,3-
dione disodium (CNQX), threo ifenprodil hemitartrate, 3-chloro-4-fluoro-N-[4-[[2-
(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulfonamide (TCN-201), NVP-AAM077 were 
from Tocris; dopamine hydrochloride (DA) was from Sigma.
Drugs were bath-applied by switching the Kreb’s solution to one containing known concentrations 
of drugs. Drugs applied in the recording chamber were delivered for at least 10 minutes before 
recording AMPA-EPSC and NMDA-EPSC and maintained throughout the experiment. We used 
two different mouse antibodies against α-syn: a monoclonal IgG1 Ab, raised against the amino acid 
121-125 of human α-syn, which recognizes all forms of the protein (Syn211, Santa Cruz 
Biotechnology, Inc.,) (El-Agnaf et al., 2003) and a monoclonal IgG1 Ab which has a higher affinity 
to oligomers more than α-syn fibrils (SynO2) (Vaikath et al., 2015). Abs and α-syn were provided 
by Prof. O. El-Agnaf (U.A.E. University, United Arab Emirates). Corticostriatal slices were 
incubated in a solution containing 8.6 µg α-syn, corresponding to a dose of 30 nM, plus the Ab for 1 
hour (1:1, µg/µg). The Syn211 Ab was further diluted 1:10 (0.043 µg/ml) and 1:100 (0.0043 
µg/ml), while SynO2 Ab was used at dilution 1:10.000 (4.3 x10-5 µg/ml).
RESULTS
Alpha-synuclein does not affect basal membrane properties and LTD but impairs LTP in 
striatal SPNs
In order to characterize the α-syn effect on striatal SPNs we first explored the effect of this protein 
on the basal membrane properties performing patch-clamp recordings of SPNs in striatal slices 
obtained from 2-3 months-old rats. The current-voltage relationship was evaluated applying 
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hyperpolarizing and depolarizing steps of currents to SPNs of control slices and of slices incubated 
for 1-hour with 30 nM monomeric/oligomeric α-syn freshly diluted in the Kreb’s solution (see 
Materials and Methods). We found that the measured electrical properties were unaffected by α-syn 
since statistical analysis showed no significant differences in the I-V curves between SPNs recorded 
in control slices (n=5) and in slices treated with α-syn (n=4) (control vs α-syn, P>0.05) (Fig. 1A). 
Striatal slices were subsequently tested to assess the effect of 30 nM α-syn on long-term changes of 
synaptic transmission (LTD and LTP) of SPNs. EPSCs were recorded for 10 minutes to obtain a 
stable baseline and then for 30 minutes after the application of the HFS protocol. We found that 
SPNs recorded in control and in α-syn-incubated slices showed LTD of similar amplitudes 
(Calabresi et al., 1992a). In fact, the EPSCs amplitude was reduced by 46.0 ± 2.8% (n=6) and by 
49.8 ± 2.1% (n=6) in SPNs from control slices and α-syn-incubated slices, respectively (t(10)=1.094, 
P<0.05, pre vs 30min after HFS, Fig. 1B). To explore the effect of α-syn on SPNs LTP, EPSCs 
were recorded before and for 30 minutes after the application of magnesium free HFS protocol. 
While SPNs from control slices showed a robust LTP of 148.7 ± 3.2% (n=7, t(6)=15.37, P<0.001), 
neurons from α-syn-treated slices showed no LTP (n=7, P>0.05, pre vs 30min after HFS, Fig. 1C).
We also analysed the EPSC amplitude, measured 30 min after the induction of the LTP, in the 
presence of different concentrations of α-syn. We found that while 3 nM α-syn (n=6) did not affect 
this parameter, both 10 nM (n=7) and 30 nM (n=7) produced a significant reduction. Higher 
concentrations of α-syn (300 nM, n=6) did not further decrease the EPSC amplitude (Fig. 1D). 
It has been postulated a major detrimental effect of α-syn is the reduction of striatal dopamine (DA) 
levels (Ghiglieri et al., 2018), thus the α-syn-induced LTP impairment could be induced by lower 
DA levels in the synaptic cleft. To test this hypothesis, 30 µM exogenous DA were bath applied 
before the HFS in order to obtain a recovery of the LTP in the presence of α-syn (n=6). 
Surprisingly, DA failed to restore this form of synaptic plasticity suggesting that other non-
dopaminergic mechanisms might be involved in the loss of LTP in the presence of α-syn (Fig. 1E).  
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In order to investigate the time- and dose-dependent formation of α-syn oligomers in the Krebs 
solution used for the electrophysiological experiments, α-syn samples at time 0 and 30 min were 
taken and measured by specific oligomeric ELISA. As expected, the formation of α-syn oligomers 
was time- and dose-dependent (Fig. 1F, *P<0.05, **P<0.01), as higher level of α-syn oligomers 
were detected in the 300 nM α-syn samples collected at 30 min. To evaluate the presence of fibrils 
we used the Thioflavin T (ThT) fluorescence assay; the results clearly show that little fluorescence 
was detected with the 30 nM concentration, independently on the timing of sampling (Fig. 1G, 
***P<0.001). 
Alpha-synuclein affects SPNs glutamatergic transmission by selectively targeting the GluN2A-
NMDAR current, but not the GluN2B-NMDAR and AMPAR currents
We then evaluated the effect of α-syn on the AMPA- and NMDA-EPSCs since both these glutamate 
receptors exert a pivotal role in the long-term changes of synaptic plasticity of SPNs. To isolate 
AMPA-EPSCs, SPNs were recorded in the presence of 50 µM of the NMDAR antagonist APV and 
50 µM of the GABAAR antagonist picrotoxin. After obtaining stable EPSCs for 10 minutes, 
synaptic currents were measured in the presence of 30 nM α-syn for additional 10 minutes. We 
found no significant difference between AMPA-EPSCs recorded before and following α-syn 
application (n=6, P>0.05, Fig. 2A). We also evaluated the AMPAR rectification index (RI) 
calculated in control conditions and in the presence of 30 nM α-syn (Fig. 2B). Statistical analysis 
shows that in these conditions the AMPA RI was not significantly different from that measured 
before α-syn application (n=6, P>0.05, Fig. 2B), further suggesting that in SPNs α-syn does not 
alter the function of AMPAR.
We also explored whether α-syn affected the NMDAR by targeting the GluN2A- or the GluN2B-
mediated NMDA-EPSC (GluN2A-EPSC and GluN2B-EPSC). To isolate the GluN2A-EPSC, 
synaptic responses were recorded in the presence of 10 µM of the AMPAR antagonist CNQX, 50 
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µM picrotoxin and 3 μM of the GluN2B antagonist ifenprodil. We found that after recording a 
stable baseline for 10 minutes, the subsequent application of 30 nM α-syn significantly reduced the 
GluN2A-EPSC by 40.8 ± 6.1% (n=6, t(5)=6.684, P<0.05, Fig. 2C). We subsequently isolated the 
GluN2B-EPSC by recording synaptic responses in the presence of CNQX, 50 nM of the GluN2A 
antagonist NVP-AAM077 and picrotoxin. The application of 30 nM α-syn did not affect the 
GluN2B-EPSC (n=6, P>0.05, Fig. 2D). Similarly, we found that the GluN2B-EPSC, isolated using 
the more specific GluN2A antagonist TCN-201 (10 µM), was not significantly affected by α-syn 
application (n=6, P>0.05, Fig. 2E). Taken together these findings show that α-syn affects the SPNs 
NMDA-EPSC selectively targeting the GluN2A-containing NMDA receptors. Moreover, we also 
evaluated, by WB analysis in a triton-insoluble post-synaptic fraction (TIF), the possibility that 
alterations in the molecular composition of ionotropic glutamate receptors may lead to the observed 
synaptic alterations in SPNs induced by α-syn. In line with the electrophysiological experiments, we 
found that incubation (1-hour) of the slices in 30 nM α-syn did not alter GluA1 and GluA2 AMPAR 
subunit synaptic levels (n=8, P>0.05, α-syn vs control, Fig. 2F) while it significantly reduced the 
GluN2A but not GluN2B NMDAR subunit synaptic levels (n=6, GluN2A, P=0.014, α-syn vs 
control, Fig. 2G).
GluN2A but not GluN2B NMDAR subunit plays a critical role in the induction of LTP in 
SPNs 
To ascertain the involvement of GluN2A and GluN2B NMDAR subunits in LTP, we first induced 
this form of synaptic plasticity in the presence of 3 µM of the GluN2B antagonist ifenprodil, to 
isolate the GluN2A-EPSC. In these conditions we found a normal LTP since the increase of EPSCs 
amplitude obtained after the delivery of HFS protocol was not different from that one of control 
slices (control, 147.2 ± 3.0%, n=6; ifenprodil, 143.3 ± 2.8%, n=5, P>0.05, Supplementary Fig. 1). 
Conversely, the application of the GluN2A antagonists NVP-AAM077 (50 nM, n=5) or TCN-201 
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(10 µM, n=5) completely prevented the LTP induction (P>0.05, Supplementary Fig. 1), further 
confirming that the NMDAR expressing the GluN2A subunit mediates the LTP induction of striatal 
SPNs.
Alpha-synuclein affects LTP and NMDAR-mediated synaptic currents in SPNs of both direct 
and indirect pathways
To investigate whether SPNs expressing either the D1-like or D2-like DA receptors (Calabresi et 
al., 2014) were differentially affected by α-syn, we recorded SPNs from striatal slices of dtTomato 
mice. In these animals, we firstly optically identified fluorescent (D1-like expressing: D1R-
positive) and non-fluorescent (putative D2-like expressing: putative D2R-positive) SPNs (Fig. 3A). 
Subsequently, we patch-clamped SPNs for an electrophysiological characterization and for LTP 
analysis in both these neuronal sub-populations. We found that both fluorescent (D1R-positive) and 
non-fluorescent (putative D2R-positive) SPNs showed LTP of similar amplitude. In fact, 30 
minutes after the induction of the HFS protocol, the EPSC amplitude was increased respect to the 
baseline by 134.6 ± 4.0% (n=6, t(5)=11.33, P<0.001) and 137.1 ± 5.9% (n=6, t(5)=5.452, P<0.001), 
respectively in fluorescent and non-fluorescent SPNs (Fig. 3B). 
Moreover, we aimed at verifying whether α-syn equally affected LTP of SPNs of both neuronal 
sub-populations. Striatal slices from dtTomato mice were incubated for 1-hour with 30 nM α-syn. 
In these conditions we found that the induction of LTP was completely prevented in both 
fluorescent (n=5, P>0.05) and non-fluorescent SPNs (n=5, P>0.05) (Fig. 3C-D). 
Since α-syn affected NMDA-EPSCs (Fig. 2C-E), we tested whether this glutamatergic current was 
differentially altered by α-syn in SPNs expressing and not expressing (putative D2R-positive) the 
D1 DA receptor. The NMDA-EPSC amplitudes were recorded in pharmacological isolation in the 
presence of 50 µM picrotoxin plus 10 µM CNQX in both fluorescent and non-fluorescent SPNs of 
dtTomato mice. After acquiring a stable baseline for 10 minutes, 30 nM α-syn was bath applied for 
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subsequent 10 minutes. We found that α-syn significantly reduced the NMDA-EPSC in both SPN 
populations. The EPSCs were reduced by 27.2 ± 4.2% in D1R-positive SPNs (n=6, t(5)=6.510, 
P<0.05, Fig. 3E) and by 30.1 ± 6.3% in putative D2R-positive SPNs (n=4, t(3)=4.764, P<0.05, Fig. 
3F) and the amplitude of these reductions was similar in these two groups of SPNs (P>0.05). These 
findings suggest that α-syn exerts similar effects in SPNs of the direct and indirect basal ganglia 
pathways equally affecting the NMDAR-mediated synaptic current.
Alpha-synuclein affects the NMDAR-current evoked in SPNs by cortico-striatal and thalamo-
striatal optical stimulation
Our data suggest that α-syn reduced the GluN2A-EPSC amplitude following the stimulation of 
glutamatergic afferents to the striatum. However, striatal SPNs receive glutamatergic inputs by both 
the cortex and the thalamus and these pathways might be differentially regulated by 
pharmacological agents (Wu et al., 2015). Thus, we investigated whether α-syn affected the 
NMDAR-mediated transmission in cortico-striatal synapses as well as in the thalamo-striatal 
pathway by using an optogenetic approach to better dissect inputs from these two brain structures. 
We firstly recorded NMDA-EPSCs in pharmacological isolation to evaluate the contribution of the 
GluN2A and GluN2B NMDAR subunits in cortico-striatal and thalamo-striatal synapses and then 
analysed the effect of α-syn on these currents (Fig. 4A-H). SPNs EPSCs, evoked by optical 
stimulation of cortico-striatal projections, were recorded from Thy1-ChR2-YFP mice. GluN2A- or 
GluN2B-EPSCs were isolated in the presence of 50 µM picrotoxin, 10 µM CNQX and 3 µM 
ifenprodil (GluN2B antagonist) or 10 µM TCN-201 (GluN2A antagonist), respectively. 
We found that the NMDA-EPSC was significantly reduced by 45.46 ± 3.29% in the presence of the 
solution containing ifenprodil and by 35.04 ± 5.47% in that with TCN-201 (ifenprodil, n=6, 
t(5)=13.86, P<0.0001; TCN-201, n=6, t(5)=6.405, P<0.05, Fig. 4C). We subsequently tested the 
effect of α-syn on the isolated GluN2A- and GluN2B-EPSC. 30 nM α-syn significantly reduced the 
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GluN2A-EPSC by 40.82 ± 4.46% (n=6, t(5)=9.148, P<0.05, Fig. 4D). This effect was observed at 5, 
but not at 2 minutes, after the α-syn application (at least n=4 for all the time points, P<0.001, Fig. 
4D). Notably, longer α-syn applications (10 minutes) did not further decrease the NMDA current. 
Interestingly, we found no effect of α-syn on the GluN2B-EPSC at all time-points tested (at least 
n=4 for all time points, P>0.05, Fig. 4D).
Striatal SPNs EPSCs were also evoked by optical stimulation of the thalamus of Thy1-ChR2-YFP 
mice to evaluate the contribution of the GluN2A and GluN2B currents in the NMDAR response 
activated by thalamic glutamatergic fibres. NMDA-EPSCs, recorded in the presence of picrotoxin 
plus CNQX, were significantly reduced by 34.08 ± 2.87% in the presence of ifenprodil (n=5, 
t(4)=11.87, P<0.05, Fig. 4F) and by 32.98 ± 3.12% in TCN-201 (n=6, t(5)=10.57, P<0.05, Fig. 4F).
Isolated GluN2A and GluN2B currents were subsequently measured in the presence of α-syn. We 
found that in these conditions the GluN2A-EPSCs were reduced by 42.35 ± 4.0% (n=7, t(6)=10.58, 
P<0.0001, Fig. 4G) while, similarly to what observed for GluN2B-EPSCs evoked by optical 
cortico-striatal stimulation, α-syn had no effect on the GluN2B currents (n=7, P>0.05, Fig. 4G). 
This effect was observed at 5 after the α-syn application. Notably, also in this case longer α-syn 
applications did not further decrease the NMDA current and we found no effect of α-syn on the 
GluN2B-EPSC at all time-points tested (at least n=3 for all time points, P>0.05, Fig. 4G).
Monoclonal antibodies targeting α-synuclein rescue the impairment of LTP 
Alpha-synuclein is a small protein with intrinsic tendency to aggregate. Oligomeric forms of the 
protein can impair neuronal function (Diogenes et al., 2012; Rockenstein et al., 2014). Accordingly, 
we found that 30 nM α-syn cause LTP loss in SPNs by affecting the GluN2A NMDAR-mediated 
current. To counteract the effect of α-syn on SPN LTP we used the monoclonal Ab Syn211, that 
recognizes all forms of human α-syn (Giasson et al., 2000) and the Ab SynO2, which mainly 
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recognizes early soluble oligomers and late aggregates amyloid fibrils of α-syn (Majbour et al., 
2016).
Incubation of the slices for 1 hour with the Syn211 Ab 1:10 alone did not affect LTP (158.3 ± 7.4%, 
n=7, t(6)=6.863, P<0.001, Fig. 5A). However, incubation of the slices for 1 hour with the Syn211 Ab 
1:10 in combination with 30 nM α-syn was able to prevent the loss of LTP induced by α-syn (153.0 
± 54.9%, n=7, t(6)=10.52, P<0.0001, Fig. 5A). Conversely, a lower Ab concentration (1:100) was 
not sufficient to counteract the α-syn effect on LTP amplitude; in fact, SPNs recorded in the 
presence of Syn211 Ab 1:100 plus 30 nM α-syn showed no LTP (n=7, P>0.05, Supplementary Fig. 
2).
We subsequently tested the effect of SynO2 Ab, which recognizes oligomeric forms of α-syn more 
specifically than fibrillar forms. We found that while a very low concentration (1:10.000) of this Ab 
did not affect LTP per se (143.2 ± 3.8%, n=7, t(6)=13.33, P<0.0001, Fig. 5B), it rescued this form of 
synaptic plasticity when incubated in the presence of 30 nM α-syn (140.9 ± 3.8%, n=7, t(6)=12.01, 
P<0.0001, Fig. 5B). Taken together these data suggest that Abs against α-syn represent a valid tool 
for preventing the detrimental effect of α-syn on striatal synaptic plasticity.
Next, we tested the ability of SynO2 and Syn211 antibodies to capture α-syn oligomers formed 
during incubation in Krebs solution. We conducted immunoprecipitation experiment with the 
samples collected at time 0 and 30 minutes with antibodies (SynO2 or Syn211) and estimated the α-
syn oligomers left in the sample using our oligomeric ELISA. Interestingly, when the samples were 
immunoprecipitated using SynO2, the supernatant contained very low levels of α-syn oligomers 
with both high and low concentrations (Fig. 5C, left and right panel respectively), suggesting 
sequestration of α-syn oligomers species with high efficacy (Fig. 5C, **P<0.01). Whereas, 
incubation with Syn211 antibody exerted a milder effect, and higher levels of α-syn oligomers were 
detected in the supernatant (Fig. 5C, **P<0.01). This dose-response nicely parallels that observed in 
their relative efficacy in rescuing the LTP impairment induced by α-syn oligomers (Fig. 5A-B).
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Incubation with alpha-synuclein specifically affects GluN2A localization at the post-synaptic 
membrane
Notably, incubation of the slices with Syn211 Ab 1:10 or with SynO2 Ab 1:10.000 in combination 
with 30 nM α-syn was sufficient to prevent the reduction of GluN2A levels in the postsynaptic 
compartment (n=6-11, P<0.01, control vs α-syn; P<0.05, Syn211 plus α-syn vs α-syn; P<0.05, 
SynO2 plus α-syn vs α-syn, Fig. 5D-E). In agreement with LTP results (see Supplementary Fig. 2), 
incubation of the slices with Syn211 Ab 1:100 did not revert the effect of 30 nM α-syn on GluN2A 
synaptic levels (n=7-11, P<0.01, control vs α-syn, Supplementary Fig. 3). No effect of 30 nM α-syn 
on synaptic localization of GluN2B subunit of NMDAR or GluA1 and GluA2 subunits of AMPAR 
was observed either in absence or presence of co-incubation with Syn211 Ab 1:10 or with SynO2 
Ab 1:10.000 (Supplementary Fig. 4A-D). Overall these results indicate that the observed decrease 
in GluN2A-NMDARs current induced by α-syn is directly correlated to a reduction of the synaptic 
availability of this receptor subunit.
Intrastriatal injections of alpha-synuclein protofibrils impairs visuo-spatial learning
To test in vivo the effects of human α-syn aggregates, we injected directly into the dorsal striatum 
preformed α-syn fibrils (PFF), which is an already characterized progressive model of 
synucleinopathy. In fact, using a similar approach, a time-dependent spreading of α-syn and 
neuronal degeneration has been reported about 9 months after the injection (Luk et al., 2012). 
Figure 6A shows the Transmission Electron Microscopy (TEM) analysis of protofibrils and shorter 
aggregates (putative oligomers) injected into the rat striatum. We decided to test the effects at 6 
weeks post-injection (Fig. 7A-B); at this time point aggregates, and other α-syn forms, are 
evidenced through their reaction with the phospho-Ser129hu-α-Syn antibody (in red) and remained 
localized into the dorsal striatum (Fig. 6B-C).
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To test whether behavioural performance was affected, PBS- and α-syn-injected rats were subjected 
to a visuo-spatial learning task. The task is based on a habituation/dishabituation paradigm in which 
animals during the habituation phase (from session 2 to session 7), through direct exploration, 
acquire information about 3 different objects and their spatial location in the arena (Fig. 7A-B). 
After this acquisition phase, one of the objects is displaced (session 8); the spatial preference for the 
displaced object (DO) over the non-displaced objects (NDO) is an index of spatial novelty 
detection. As reported in figure 7B, α-syn-injected rats, as well as PBS-injected animals, explore the 
objects during the habituation phase, reducing the exploration time across sessions [Treatment 
(F1,15=0.026; P=0.874); Exploration (F5,75=7.673; P<0.0001); Exploration x Treatment (F5,75=0.75; 
P=0.589)] (Fig. 7B). After the spatial displacement the PBS group showed a preference for DO as 
compared to NDO1 and NDO2, as expected; in contrast, the α-syn-injected group did not show any 
preference for the DO [Treatment (F1,15=0.152; P=0.702); DO (F2,30=3.387; P=0.047); DO x 
Treatment (F2,30=3.347; P=0.049)]. This effect was not due to a general effect on object exploration, 
attention or motivation to explore novelty, as both groups showed a clear preference when the same 
object was substituted with a new one (SO) during the last testing session [Treatment (F1,15=0.348; 
P=0.564); SO (F2,30=15.153; P<0.0001); SO x Treatment (F2,30=0.87; P=0.429)].
Intrastriatal injections of alpha-synuclein aggregates impair the SPNs GluN2A-bearing 
NMDAR-current
We subsequently attempted to test the possible causal link among the presence of striatal α-syn 
aggregates, the synaptic transmission deficits, as observed in the in vitro electrophysiological 
experiments using α-syn oligomers, and the behavioural deficits of α-syn-injected rats in 
performing the visuo-spatial learning task. 
A group of human α-syn- and sham-injected rats were sacrificed one week after the behavioural 
task. SPNs of the two groups were patch-clamped and EPSCs were evoked at -80 mV holding 
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potential, in the presence of 50 µM picrotoxin, and at +40 mV, in picrotoxin plus 10 µM CNQX, to 
calculate the NMDA/AMPA ratio of the synaptic current. Statistical analysis revealed that SPNs of 
α-syn-injected rats presented reduced NMDA/AMPA ratio in respect to sham-injected animals (α-
syn vs sham, n=5 for each group, t-test, t(8)=6.6, P<0.001; Fig. 7C). In addition, since α-syn 
oligomers specifically reduced the GluN2A-bearing NMDAR-currents (Fig. 2C), EPSCs of SPNs 
from α-syn- and sham-injected rats were also recorded at +40 mV holding current in the presence of 
CNQX plus 3 µM ifenprodil to measure the GluN2A-EPSC amplitude. We found that in SPNs of α-
syn-injected rats the GluN2A-current was significantly smaller than that of sham rats (α-syn vs 
sham in ifenprodil, t-test, t(11)=2.2, P<0.05; Fig. 7D) confirming that the spreading of α-syn 
aggregates into the striatum affects the striatal synaptic transmission by reducing the SPN GluN2A-
NMDA current with significant implications on behavioural learning. 
       
Behavioural effects produced by intrastriatal injection of oligomeric alpha-synuclein
Intrastriatal injections of human α-syn aggregates, containing protofibrils but also shorter forms (see 
Fig. 6A), clearly produced behavioural and synaptic alterations (See Fig. 7). These alterations could 
be due either to the action of oligomeric and monomeric α-syn forms, similar to those applied in our 
in vitro experiments, or to the critical presence of fibrillary PFF forms of this protein. Thus, to 
better dissect the pathogenetic role of different species of α-syn (protofibrils versus oligomers and 
monomers), we performed a similar in vivo intrastriatal injection with α-syn cocktail mainly 
containing oligomers (OLIGO).  
We injected the α-syn cocktail (α-syn OLIGO) directly into the dorsal striatum (Fig. 8A-B), using 
the same protocol used for PFF. As previously indicated for PFF (see Fig. 6A), also the presence of 
α-syn OLIGO has been detected by TEM (Fig. 8A). Electron Microscopy was always used to 
analyse the quality of α-syn preparations before injection into the rat striatum confirming the 
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presence of oligomers with very few protofibrils (Fig. 8A). In addition, α-syn OLIGO has been 
confirmed by immunofluorescence with antibodies against α-syn and phospho-α-syn (Fig. 8B-C). 
 As reported in Fig. 8D-F, α-syn OLIGO-injected rats, as well as PBS-injected animals, explore the 
objects during the habituation phase, reducing the exploration time across sessions [Treatment 
(F1,10=0.86; P=0.375); Exploration (F5,50=9.65; P<0.0001); Exploration x Treatment (F5,50=0.45; 
P=0.80)] (Fig. 8D). The α-syn OLIGO-injected group did not show any preference for the DO 
[Treatment (F1,10=0.138; P=0.702); DO (F2,20=8.039; P=0.0027); DO x Treatment (F2,20=4.7; 
P=0.02)] and SO [Treatment (F1,10=0.713; P=0.41); SO (F2,20=8.70; P=0.0019); SO x Treatment 
(F2,20=3.99; P=0.03)] (Fig. 8E-F), thus suggesting that it impaired both spatial and object novelty 
recognition, in the absence of major degeneration of TH positive terminals in the striatum 
(Supplementary Fig. 5). 
Analysis of basal motor activity in the open field reveals that at this early stage neither animals 
injected with protofibrils nor animals injected with α-syn OLIGO show significant changes of 
motor behaviour (Supplementary Fig. 6).
DISCUSSION
In this study we have investigated the effects of exogenous human α-syn on synaptic transmission 
and plasticity of SPNs, the main neuronal subtype of the striatum. We obtained four novel findings: 
1) α-syn impairs LTP by altering the activity of the GluN2A-containing NMDARs in SPNs 
belonging to the direct and indirect basal ganglia pathways; 2) α-syn produces a reduction of 
NMDAR-mediated currents in SPNs optically activated by stimulation of either cortical or thalamic 
afferents; 3) the application of α-syn-neutralizing antibodies prevents the widespread impairment of 
striatal LTP; 4) intrastriatal injection of α-syn PFF produces deficits in visuo-spatial learning and 
GluN2A NMDA receptor function; 5) the intrastriatal injection of oligomers (α-syn OLIGO) 
mimics the behavioural effects produced by PFF, causing an even more severe visuo-spatial 
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alteration. These data suggest that oligomeric/monomeric forms play a more relevant role than 
fibrillary forms on striatal-dependent behaviour.
Striatal dysfunction as an early effect of alpha-synuclein toxicity 
The complex alterations of the basal ganglia pathways in Parkinson’s disease involve degeneration 
of nigral DA neurons that leads to reduced striatal DA content and impaired synaptic plasticity of 
SPNs (Calabresi et al., 2007; Gerfen and Surmeier, 2011). These changes are accompanied by 
accumulation of α-syn (Spillantini and Goedert, 2016), exerting a toxic role in Parkinson’s disease 
in its oligomeric forms (Conway et al., 1998; Winner et al., 2011; Rockenstein et al., 2014) rather 
than in the fibrillar state or when clustered into LBs (Ghosh et al., 2015). 
Although it has been previously reported that in the hippocampus micromolar concentrations of 
extracellular α-syn oligomers are able to impair LTP and to increase basal synaptic transmission 
through a NMDAR-mediated action (Diogenes et al., 2012), little is known on the direct effects of 
α-syn oligomers on striatal neurotransmission, a fundamental player in the regulation of voluntary 
motor function in physiological conditions and in Parkinson’s disease. Our findings, demonstrating 
widespread involvement of much lower (nanomolar) concentrations of α-syn oligomers in the 
alteration of synaptic transmission in striatal SPNs, are particularly relevant given the role exerted 
by altered forms of this protein in Parkinson’s disease (Polymeropoulos et al., 1997; Spillantini et 
al., 1997; Vekrellis et al., 2011). These results extend our previous findings demonstrating that α-
syn oligomers is able to block LTP of striatal ChIs at lower concentrations (3 nM) respect to that 
effective on SPNs in the present study (30 nM), by selectively modulating the GluN2D-expressing 
NMDA receptors (Tozzi et al., 2016). Taken together these findings suggest that increasing 
concentrations of α-syn oligomers progressively affect NMDAR-mediated synaptic plasticity on 
distinct neuronal populations indicating that the vulnerability to this protein is cell- and region-
specific.
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Distinct vulnerability of different NMDA receptor subunits to alpha-synuclein 
We found that α-syn impairs NMDAR-dependent LTP in striatal SPNs with no detrimental effect 
on LTD, according to the observation that this latter form of synaptic plasticity in the striatum does 
not require NMDAR activation (Calabresi et al., 2007).
We observed that α-syn affected SPNs glutamatergic transmission by selectively affecting GluN2A-
expressing NMDAR currents. This is a remarkable finding since NMDAR bearing the GluN2A 
receptor subunit is necessary for LTP induction (Paoletti et al., 2013). Accordingly, here we have 
shown that activity-dependent LTP in SPNs is blocked by antagonists acting on the GluN2A, but 
not GluN2B, NMDAR subunit. In line with these findings, our data rule out significant effects of α-
syn on currents mediated by GluN2B subunit of NMDAR and by AMPAR. Moreover, as evidenced 
by WB assay, α-syn is able to lower the synaptic localization of GluN2A NMDAR subunit in 
striatal slices without affecting levels of other subunits of ionotropic glutamate receptors.
Alpha-synuclein alters NMDAR-mediated excitatory transmission at SPNs of both direct and 
indirect pathways 
According to the classical view, striato-nigral SPNs express D1-like DA receptors, representing the 
direct pathway of the basal ganglia, while striato-pallidal SPNs express the D2-like DA receptors, 
representing neurons of the indirect pathway (Gerfen et al., 1990; Gerfen and Surmeier, 2011). This 
differential molecular expression of DA receptors is important for two functional reasons. Firstly, 
activation of D1 DA receptor signalling is required for LTP (Reynolds et al., 2001; Calabresi et al., 
2007), while D2 DA receptors are mainly implicated in LTD (Kreitzer and Malenka, 2007; Shen et 
al., 2008). The second aspect regards their possible different role in the motor function. In fact, 
activation of the direct pathway by DA is thought to promote movement initiation, whereas the 
activation of the indirect pathway would be involved in inhibition of motor activity (Mink, 2003; 
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Nambu, 2008; Gerfen and Surmeier, 2011). In apparent contrast with this dichotomous view, more 
recent studies propose a new vision of the basal ganglia functionality, based on signalling 
integration at different levels (Cui et al., 2013; Calabresi et al., 2014). Anatomical evidences 
reported the existence of “bridging collaterals”, axon collaterals connecting neurons of the direct 
and indirect pathways (Cazorla et al., 2015). On the basis of these different theories, using striatal 
slices from dtTomato mice, we investigated whether the alteration of LTP caused by α-syn occurs 
either in a single or in both sub-populations of SPNs. We found that the detrimental effect of α-syn 
on LTP and on NMDAR synaptic currents is evident both in D1- and D2-expressing SPNs. 
Cortico-striatal and thalamo-striatal glutamatergic inputs are equally affected by alpha-
synuclein
Further evidence of the widespread toxic effect of α-syn on striatal synapses come from our 
investigation of the NMDAR-mediated current in cortico-striatal and in thalamo-striatal pathways. 
The striatum receives glutamatergic inputs both from cerebral cortex and thalamus (McGeorge and 
Faull, 1989; Smith et al., 2004; Doig et al., 2010) and these two systems act in concert to regulate 
motor function differentially contributing to specific tasks. Cortical afferents projecting to the 
dorsal striatum are mainly involved in planning, learning and execution of motor behaviour (Jog et 
al., 1999), whereas the thalamo-striatal inputs modulate attention-related stimuli, being engaged in 
behavioural switching, reinforcement functions and attention set-shifting (Smith et al., 2011). 
Moreover, these two systems might differentially contribute, in Parkinson’s disease patients, to the 
generation of glutamatergic dysfunction in the striatum. Thus, we have investigated a possible 
differential effect of α-syn on cortico-striatal versus thalamo-striatal synapses. To this aim we used 
a distinct optical stimulation of the two pathways using para-horizontal brain slices. Compared to 
coronal slices, this particular tissue preparation allows to specifically discriminating the two 
projections converging on SPNs (Smeal et al., 2007). Interestingly, α-syn caused a similar reduction 
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of GluN2A NMDAR current evoked by selectively activating either cortical or thalamic fibres. This 
finding, together with previous experiments performed with electrical stimulation, supports the idea 
that α-syn causes a widespread alteration of excitatory synaptic transmission within the striatum.
The widespread striatal synaptic dysfunction can be prevented by antibodies against alpha-
synuclein
Several studies described the consequences of the application of Abs against α-syn, reporting 
improvement in intracellular α-syn aggregates clearing, reduction of α-syn fibrils propagation, 
together with attenuation of memory and neurodegenerative deficits (Spencer et al., 2017). In the 
attempt to clarify whether specific monoclonal Abs against α-syn exert protective effects over 
synaptic plasticity, we employed Syn211 Ab and SynO2 Ab; both Abs recognizing all forms of 
human α-syn, however, SynO2 Ab is much more potent than Syn211 Ab in binding α-syn 
oligomers and fibrils (Giasson et al., 2000; Majbour et al., 2016). The depletion experiment we 
performed, confirmed that either Syn211 Ab or SynO2 Ab shows affinity for α-syn oligomeric 
aggregates, with a different binding specificity between the two Abs.  Interestingly, we found that, 
an overlapping dose-response effect of the two Abs in rescuing the LTP impairment induced by α-
syn in striatal SPNs. The two Abs also prevented the reduction of GluN2A expression levels caused 
by α-syn. This protective effect is consistent with our observation that α-syn alters LTP affecting 
NMDAR-mediated currents, in particular the GluN2A subunit. Interestingly, the PFF preparation 
injected intrastriatally in in vivo experiments contained both OLIGO and PFF aggregates. 
Differential effect of fibrillar versus oligomeric forms of alpha-synuclein on visuo-spatial 
learning
Accumulating in vivo evidence showed that α-syn protofibrils directly injected in the striatum lead 
to a time-dependent spreading accompanied by neuronal loss and motor deficits in mice within 9 
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months after the injection (Luk et al., 2012). In this study we aimed at verifying whether the 
pathological interaction between α-syn aggregates and NMDA receptors in the striatum led to 
impaired behavioural function; for this reason, we focused on an early time point when the 
aggregates remained localized within the striatum. To dissect the behavioural effects of α-syn 
aggregates we used a visuo-spatial learning task that we have previously shown to rely on NMDA 
receptors activation in the dorsal striatum (De Leonibus et al., 2003; De Leonibus et al., 2005).  α-
syn PFF injected rats show impaired spatial novelty detection, although they normally explore the 
objects during the habituation phase and can discriminate a new object among familiar ones. 
Interestingly, the intrastriatal injection of oligomers mimics the behavioural effects produced by 
PFF. This effect is even more severe than that one induced by PFF injection since while fibrils only 
affect the ability to discriminate the object displacement, oligomers impair both spatial and object 
novelty recognition. This is surprising considering that the PFF preparation injected intrastriatally in 
in vivo experiments contained both OLIGO and PFF aggregates and that the α-syn cocktail 
producing the rapid synaptic and plastic alterations mainly contain oligomeric/monomeric forms, 
but little or no fibrils, as confirmed by the ThT analyses. 
While the effect of in vivo injection of α-syn on SPN NMDAR currents does not provide a direct 
mechanistic explanation that NMDAR changes are responsible of the described behavioural 
alteration, it confirms that α-syn is able to produce molecular changes affecting the function of this 
receptor with possible behavioural consequences.
Our experiments in α-syn-injected rats showed specific deficits in visuo-spatial exploration while 
locomotor activity was not affected respect to control animals. It possible that we failed to detect 
motor deficits because of the site and/or size of the injection within the striatum.  
All together, these findings suggest that oligomeric α-syn itself is harmful for synaptic plasticity and 
behavioural functions of the dorsal striatum. We speculate that further α-syn aggregation into 
protofibrils might limit their direct impact within the area of injection, while favouring their 
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spreading across brain regions as previously reported (Luk et al., 2012). Further studies are 
necessary to address this issue. The translational relevance of this preclinical data for PD are 
evidenced by findings in humans showing visuo-spatial learning deficit in de novo PD patients 
showing spatial location deficits (Pillon et al., 1997). 
Conclusions
Although the role of α-syn in the pathogenesis of Parkinson’s disease has been deeply investigated, 
little is known on the effect of α-syn on striatal synaptic transmission and related early behavioural 
alterations. Our research demonstrates a widespread and NMDAR-related dysfunction of striatal 
synaptic network induced by α-syn. We report for the first time that α-syn, through interaction with 
GluN2A-bearing NMDAR, impairs LTP in SPNs of the direct and indirect basal ganglia pathways 
and causes visuo-spatial learning deficit. The α-syn-induced synaptopathy is also observed when 
neurons are optogenetically activated by either cortical or thalamic inputs. Notably, both plastic and 
behavioural alterations observed in our study do not seem to be dependent on dopaminergic 
degeneration. In fact, the plastic dysfunctions induced by acute in vitro application of α-syn are not 
rescued by exogenous DA. Accordingly, the observed visuo-spatial learning deficits are not 
associated with a loss of dopaminergic terminals. Moreover, the open field analysis does not show 
overt motor impairment indicating that our in vivo model recapitulates an early stage of the disease.
Finally, we provide evidence that antibodies neutralizing α-syn are effective in blocking its 
detrimental actions. Taken together these data support the use of antibodies against α-syn as a valid 
approach to preserve the functionality of synaptic plasticity in the striatal network.
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Figure legends
Figure 1. Effect of α-synuclein on the intrinsic membrane properties and synaptic plasticity of 
striatal SPNs. (A) Representative voltage traces (top) and current-voltage graph (bottom) recorded 
from SPNs during the injection of hyperpolarizing and depolarizing steps of current in control 
conditions (n=5) and in the presence of 30 nM α-syn (n=4) show no differences in the firing pattern 
discharge and intrinsic membrane properties of these neurons. (B) Examples traces (top) and time 
course (bottom) of the excitatory postsynaptic currents (EPSCs) measured before and 30 minutes 
after the application of the HFS protocol show no differences in the LTD induction in SPNs 
recorded from control slices (n=6) and from slices incubated with α-syn (n=6). (C) Paired EPSC 
traces (top) and time-course graph of the EPSC amplitude (bottom) recorded in SPNs from control 
slices (n=7) and in SPNs of slices incubated with 30 nM α-syn (n=7) before and after the delivery of 
the HFS protocol show the block of LTP in SPNs recorded from slices treated with α-syn. (D) 
Histogram showing the EPSC amplitude 30 min following the HFS protocol of SPNs recorded from 
control striatal slices and from slices incubated with increasing concentrations of α-syn (3 nM, n=6, 
10 nM, n=7, 300 nM, n=6). (E) EPSC traces (top) and time-course graph of the EPSC amplitude 
(bottom) measured in SPNs of control slices (n=7) and of slices incubated with 30 nM α-syn in the 
presence of 30 μM dopamine (DA) (n=6) bath applied before and after the HFS protocol. Data are 
represented as mean ± SEM. (F) Histogram of the ELISA shows time- and dose-dependent α-syn 
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oligomers; higher level of α-syn oligomers were detected in the 300 nM α-syn samples collected at 
30 min. (G) ThT assay shows that little fluorescence was detected with the 30 nM concentration, 
independently on the timing of sampling. In contrast, high fluorescence signal was measurable with 
the 300 nM dose. Data are reported as percentage of fluorescence registered at T0 ± SEM. *P<0.05, 
**P<0.01, ***P<0.001.
Figure 2. Effect of alpha-synuclein on AMPAR- and NMDAR-mediated currents. (A) Example 
traces (top) and histogram (bottom) showing the AMPAR-mediated synaptic current of SPNs 
recorded in pharmacological isolation, in the presence of APV and picrotoxin, before and after the 
application of 30 nM α-syn (n=6). (B) Example traces of EPSCs (top) evoked at +40 and -80 mV 
holding potential and histogram (bottom) showing the AMPAR RI of SPNs recorded in control 
conditions and in the presence of α-syn (n=6). (C) Histogram showing the averaged EPSC 
amplitude carried by the GluN2A-expressing NMDAR measured in SPNs in the presence of 
picrotoxin, CNQX and ifenprodil (open orange bar) and after subsequent addition of 30 nM α-syn 
(n=6) (filled cyan bar). The superimposed traces show EPSCs acquired at +40 mV holding potential 
of a SPN in the presence of picrotoxin + CNQX (black trace), picrotoxin + CNQX + ifenprodil 
(orange trace) and picrotoxin + CNQX + ifenprodil + α-syn (cyan trace). (D, E) Histograms 
showing the averaged EPSC amplitudes carried by the GluN2B-expressing NMDAR measured in 
SPNs in the presence of picrotoxin, CNQX and NVP-AAM077 (n=6) (D, open violet bar) or 
picrotoxin, CNQX and TCN-201 (n=6) (E, open violet bar) and in the presence of 30 nM α-syn on 
this current (n=6) (D-E, filled cyan bars). Superimposed traces showing EPSCs acquired from a 
single SPN following the application of picrotoxin + CNQX (D, black trace), picrotoxin + CNQX + 
NVP-AAM077 (D, violet trace), picrotoxin + CNQX + NVP-AAM077 + α-syn (D, cyan trace) or 
picrotoxin + CNQX (E, black trace), picrotoxin + CNQX + TCN-201 (E, violet trace), picrotoxin + 
CNQX + TCN-201 + α-syn (E, cyan trace). (F, G) Representative WB images and histograms 
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showing the effects of incubation (1 hour) of corticostriatal slices with 30 nM α-syn on the synaptic 
localization of GluA1 and GluA2 AMPAR subunits (n=8) (F) and GluN2A and GluN2B NMDAR 
subunits (n=6) (G). Data are normalized against tubulin and are shown in the graph as mean ± SEM. 
*P<0.05, **P<0.01.
Figure 3. Effect of alpha-synuclein on SPNs of the direct and indirect basal ganglia pathway. 
(A) Images of three regions acquired from a striatal slice of a transgenic Drd1a-tdTomato mouse 
showing fluorescent D1R-positive neurons (left, in red pseudocolor and top right) and a non-
fluorescent (putative D2R-positive) SPN (bottom right). (B) Example traces and time-course graph 
showing the LTP induced in both fluorescent (n=6) and non-fluorescent (n=6) SPNs after the 
delivery of the HFS protocol. (C, D) EPSC pairs (top) and time-courses graphs of the EPSC 
amplitude (bottom) showing that α-syn is able to block the LTP in both D1R-positive (n=5) (C) and 
putative D2R-positive SPNs (n=5) (D) following the HFS protocol. (E, F) Histograms showing the 
mean EPSC amplitudes of the NMDAR-mediated synaptic currents measured in pharmacological 
isolation in D1R-positive (n=6) (E) and in putative D2R-positive SPNs (n=4) (F) both in control 
condition and after the application of 30 nM α-syn. The superimposed traces show EPSCs acquired 
from a D1R-positive SPN (E) and putative D2R-positive SPN (F) in the presence of CNQX plus 
picrotoxin and in CNQX plus picrotoxin plus α-syn. Note that α-syn is able to reduce the NMDAR-
mediated current in a similar manner in these neuronal sub-populations. Data are represented as 
mean ± SEM. * P<0.05, **P<0.01.
Figure 4. Effect of alpha-synuclein on SPNs activated by optical stimulation of cortico-striatal 
and thalamo-striatal glutamatergic afferents. (A) Representative para-horizontal brain slice 
including cortical, striatal and thalamic regions and (B) scheme of a para-horizontal slice showing 
the regions of the cortex and the thalamus where optical stimulation can activate glutamatergic 
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afferents to SPNs recorded in the striatum. (C, F) Histograms of the SPNs mean NMDA-EPSC 
amplitudes optically stimulated in the cortex (C) or in the thalamus (F) in the presence of 3 µM 
ifenprodil to isolate the GluN2A-EPSC (n=6 cortex, n=5 thalamus) (orange open bar) or in the 
presence of 10 µM TCN-201 (n=6) to isolate the GluN2B-EPSC (violet open bar). Data are 
presented as percentage of the control NMDAR-EPSCs recorded in the presence of picrotoxin and 
CNQX (dotted line). (D, G) Histograms of the averaged GluN2A- and GluN2B-EPSC amplitudes 
optically stimulated in the cortex (D) or in the thalamus (G) measured in SPNs in the presence of 
picrotoxin, CNQX, ifenprodil (orange outlined bars) without (n=6) and with 30 nM α-syn (orange 
outlined, cyan filled bar) and picrotoxin, CNQX, TCN-201 (violet outlined bars) without (n=6) and 
with 30 nM α-syn (violet outlined, cyan filled bar). α-syn (n=4-6) is applied for 2, 5 and 10 min. 
Data are presented as percentage of the control GluN2A- and GluN2B-EPSCs. (E, H) Top, 
superimposed EPSCs evoked by optical stimulation of the cortex (E) or the thalamus (H) acquired 
from a SPN in the presence of picrotoxin, CNQX, ifenprodil (orange trace) and after further the 
application of 30 nM α-syn (cyan trace). Bottom, EPSCs acquired from a SPN in the presence of 
picrotoxin, CNQX, TCN-201 (violet trace) and after further the application of 30 nM α-syn (cyan 
trace). Note that α-syn significantly reduces the GluN2A- but not GluN2B-EPSC. Data are 
represented as mean ± SEM. **P<0.01, ***P<0.001.
Figure 5. Action of monoclonal antibodies against α-synuclein on SPNs synaptic plasticity. (A) 
Time-course graph showing the EPSC amplitudes of SPNs recorded before and after the LTP 
induction by HFS in slices incubated for 1 hour with 30 nM α-syn and in slices treated with Syn211 
Ab (1:10) alone (n=7) or with Syn211 Ab (1:10) plus α-syn (n=7). (B) Time-course of the SPNs 
EPSC amplitudes recorded before and after the HFS protocol in slices treated with α-syn and in 
SPNs in the presence of SynO2 Ab alone (1:10.000) (n=7) or SynO2 Ab (1:10.000) plus α-syn 
(n=7). Note that the treatment with Syn211 or SynO2 Abs is able to restore the LTP in the presence 
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of α-syn. (C) Immunoprecipitation experiment with the samples collected at time 0 and 30 min with 
antibodies (SynO2 or Syn211) estimates the α-syn oligomers left in the sample using oligomeric 
ELISA. (D, E) WB analysis for GluN2A subunit of the NMDAR in the postsynaptic fraction (TIF) 
obtained from striatal slices incubated with α-syn alone (30 nM) or with α-syn plus Syn211 (1:10) 
or Syn-O2 (1:10.000) antibodies and control slices. α-syn reduced GluN2A localization at 
postsynaptic sites, while treatment with two different anti-α-syn antibodies was able to rescue 
GluN2A levels in the TIF. Data are normalized against tubulin and are shown in the graph as mean 
± SEM. *P<0.05, **P<0.01.
Figure 6. Intra-striatal PFF alpha-synuclein injection. (A) Representative TEM image of 
preformed fibrils (PFF) preparation injected in rat striatum. (B, C) Representative brain slice of 
animals injected with α-syn in the striatum. Immunofluorescence for α-syn and phospho-Ser129-hu-
α-Syn. High levels of phosphor-Ser129-hu-α-Syn are detectable at the injection site within the 
striatum, with no spreading in the surrounding brain regions. (B) A higher magnification (60x) 
evidences the α-syn aggregates positive for phospho-Ser129hu-α-Syn. (B) Representative brain 
slice of animals injected with PBS in the striatum. No positive staining of phospho-Ser129-hu-α-
Syn is detectable in the striatum of the control group at low and high magnification (C).
Figure 7. Behavioural and electrophysiological alterations in rats injected with human alpha-
synuclein. (A) Schematic representation of the visuo-spatial novelty reaction task. Rats were 
habituated to the empty arena (S1). During the habituation phase they were allowed to explore for 6 
consecutive sessions (S2-S7) three different objects kept in constant position. Spatial learning was 
tested by displacing the position of two objects, the blu one (Displaced object-DO), and comparing 
its relative preference as compared to the non-displaced objects (NDO), the black and the purple 
once (S8). Animals were given a further session to habituate to the spatial change (S9). During the 
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last session object learning was tested by substituting one of the three objects (the blu one, 
substituted object-SO) with a new one (orange), and the other two objects with identical copies, to 
avoid the use of olfactory cues for object recognition (non-substituted objects-NSO) (S10). (B) 
Histograms showing the mean time (s) objects exploration during the habituation phase by control 
and α-syn rats (left panel); Re-exploration index of displaced DO and NDO objects after the spatial 
change, showing that control, but not α-syn rats, prefer DO vs. NDO (center panel); Re-exploration 
index of substituted SO and NSO objects after the object change, showing that both control and α-
syn rats preferred SO vs. NSO (right panel). *P<0.05 DO/SO vs. NDO/NSO, within group; # 
P<0.05 α-syn vs. control, Duncan post-hoc test. DO: displaced objects; NDO: non-displaced 
objects; SO: substituted object; NSO: non-substituted object. Control rats, n=9, α-syn rats, n=8. (C) 
Histogram showing the NMDA/AMPA ratio measured in SPNs of α-syn- (n=5) and of sham-
injected (control) rats (n=5). Traces showing an EPSC measured at +40 mV and -80 mV holding 
potential in a SPN of a control and α-syn rat. (D) Histogram showing the NMDA-current amplitude 
of SPNs from α-syn- (n=5) and control rats (n=5) before (dashed line) and after the application of 
ifenprodil to isolate the GluN2A-mediated NMDA-current. Traces showing an EPSC measured at 
+40 mV holding potential in a SPN of a control and α-syn rat before and after the application of 
ifenprodil. * P<0.05, ** P<0.01   
Figure 8. Intra-striatal oligomeric alpha-synuclein injection and behavioural alterations. (A) 
Representative TEM image of OLIGO α-syn preparation injected in rat striatum showing a majority 
of small oligomers with very few protofibrils. (B-C) Representative images of animals injected with 
α-syn in the striatum. Immunofluorescence for hu-α-syn (B) and phospho-Ser129-hu-α-Syn (C). 
40x magnification images evidences that high levels of hu-α-syn (B) and phosphor-Ser129-hu-α-
Syn (C) are detectable within the striatum. Representative images of animals injected with PBS in 
the striatum (B, C). No positive staining of phospho-Ser129-hu-α-Syn (C) is detectable in the 
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striatum of the control group at 40x magnification. Arrows indicate hu-α-syn and phospho-Ser129-
hu-α-Syn positive cells; scale bars: 50 m. (D-F) Histograms showing the mean time (s) objects 
exploration during the habituation phase by control and oligomeric α-syn rats. Re-exploration index 
of displaced DO and NDO objects after the spatial change, showing that control, but not α-syn rats, 
prefer DO vs. NDO (center panel). Re-exploration index of substituted SO and NSO objects after 
the object change, showing that both control and α-syn rats preferred SO vs. NSO (right panel). 
Control rats, n=6, oligomeric α-syn rats, n=6. *P<0.05 DO/SO vs. NDO/NSO, within group, 
Duncan post-hoc test. DO: displaced objects; NDO: non-displaced objects; SO: substituted object; 
NSO: non-substituted object.  
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Supplementary Figure 1. The induction of SPNs LTP depends on NMDA receptor expressing 
the GluN2A subunit. Example traces (top) and time-course of the EPSC amplitudes (bottom) of 
SPNs recorded in control slices, in slices treated with ifenprodil, or TCN-201 or NVP-AAM077 
before and after the application of the HFS protocol. Note the presence of LTP in control slices and 
in slices treated with ifenprodil and the absence of LTP in SPNs recorded from slices treated with 
TCN-201 or NVP-AAM077. Data are represented as mean ± SEM.
Supplementary Figure 2. Syn211 Ab (1:100) is not able to counteract the detrimental effect of 
30 nM α-synuclein. Time-course graph of the EPSC amplitudes recorded in SPNs of slices 
incubated with 30 nM α-syn and in S Ns of slices treated with Syn 211 Ab (1:100) plus α-syn. Note 
that Syn211 Ab (1:100) is not able to recover the detrimental effect of 30 nM α-syn on LTP. Data 
are represented as mean ± SEM.
Supplementary Figure 3. SynO2 Ab recognizing oligomeric α-synuclein more specifically than 
Syn211 Ab at a higher concentration of α-synuclein. α-syn was dissolved in oxygenated Ringer 
solution at a concentration of 300 nM and incubated up to 60 minutes. At different time points (0, 
15, 30, 60 minutes) aliquots of the solution were taken (200 ng) and separated using non-reducing 
SDS-PAGE. Proteins were transferred on a blotting membrane and incubated with different 
antibodies. At this concentration α-syn aggregated in SDS-resistant dimers, trimer, tetramers 
similarly to the concentration having effect on SPNs (30 nM). Additionally, high molecular weight 
oligomers were also present. The preferential binding of the two antibodies was similar to that at 30 
nM, with the SynO2 antibody recognizing oligomeric α-syn more specifically than Syn211.
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Supplementary Figure 3. Syn211 Ab (1:100) does not revert the effect of α-syn on the 
postsynaptic localization of NMDAR GluN2A subunit. WB analyses from control slices, slices 
treated with 30 nM α-syn or with α-syn plus Syn211 Ab (1:100) showed no change in the 
postsynaptic levels of NMDAR GluN2A induced by the Ab. Data are normalized against tubulin 
and are shown in the graph as mean ± SEM.
Supplementary Figure 4. No effect of α-syn in presence or absence of Syn211 or SynO2 Abs 
on the postsynaptic localization of NMDAR GluN2B and AMPAR GluA1 and GluA2 subunits. 
(A-D) WB analyses from control slices, slices treated with 30 nM α-syn or with α-syn plus Syn211 
Ab (1:10) or with α-syn plus SynO2 Ab (1:10.000) showed no change in the postsynaptic levels of 
NMDAR GluN2B and AMPAR GluA1 and GluA2 subunits. Data are normalized against tubulin 
and are shown in the graph as mean ± SEM.
Supplementary Figure 5. Representative images of animals injected with alpha-synuclein 
oligomers in the striatum; immunofluorescence for hu-α-syn and TH. (A-B) 40x magnification 
images evidences that hu-α-syn (A) is detectable within the striatum, while TH expression 
is comparable to that of control mice (B). Arrows indicate hu-α-syn positive cells; scale bars: 50 m.
Supplementary Figure 6. Motor behaviour alterations in rats injected with human oligomeric 
and PFF alpha-synuclein. Histograms showing the mean distance travelled (cm), immobility time 
(s) and maximal speed (cm/s) across time intervals in the empty open field during the first session 
(S1) of the visuo-spatial task for animals injected with protofibrils (α-syn PFF) (A) α-syn, 
oligomeric (α-syn OLIGO) (B) and relative control (PBS) injected animals. No significant group 
effects were detected.  
Page 96 of 101




Page 97 of 101




Page 98 of 101




Page 99 of 101




Page 100 of 101




Page 101 of 101




Page 102 of 101
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
